technology transfer center (mttc) and the massachusetts...

April 12, 2012

Welcome to the Eighth Early-Stage Life Sciences Technology Conference – our annual showcase for platform technologies and recently formed companies that are based on research at Massachusetts

research institutions, hospitals and universities.

The Conference continues to be one of the most important events organized by the Massachusetts Technology Transfer Center (MTTC) and the Massachusetts Association for Technology Transfer Offices (MATTO). The program is designed to provide an introduction for the investment and corporate com-munity to some of the earliest stage life-science start-ups as well as a review of some available platform technologies that are in the process of spinning-out of local institutions.

The interaction of our research community, biotech and biomed firms, as well as the investment com-munity makes Massachusetts the most vibrant life sciences community in the world. This conference highlights technologies that are emerging from the research labs and are the building blocks for new companies and products. Today’s presenters will describe to you a broad range of discoveries that could each make a significant difference in healthcare.

We again feature a large number of presenting companies and researchers. The strength of our applicant pool represents the robustness of the Massachusetts Life Sciences Cluster. We are also featuring a few start-ups that have presented at this conference before as they have made significant progress in their technology and business strategy.

We hope you enjoy today’s program. Please stay for this evening’s closing networking reception that will include poster presentations of all our pitching companies and several additional technologies and will allow all attendees the opportunity to meet individually with our researchers and entrepreneurs.

The Massachusetts Life Sciences Cluster continues to thrive. By supporting the early stage companies and researchers, you will ensure that the cluster continues to grow within the Commonwealth. Boston will again host the BIO International Convention this year and we hope that we will also see you in the exhibit hall at the conference when many of our institutions will be exhibiting.

We would like to express our sincere gratitude to Merck for hosting our event this year and our heartfelt thanks to Nutter for their sponsorship.

Dr. Abigail A. Barrow, Director, Massachusetts Technology Transfer Center

The 8th Annual Early Stage Life Sciences Conference

ii

April 12, 2012Merck Research Laboratories ∙ Boston, MA

iii

Table of ContentsConference Agenda .................................................................................................................vSpeaker Biography ....................................................................................................................7

Richard Anders, MA Medical Angels (MA2) ........................................................................................... 7Abigail Barrow, Massachusetts Technology Transfer Center ............................................................ 7Jeremy Halpern, Nutter McClennen & Fish LLP .................................................................................... 7Dr. Reid Leonard, Merck Research Ventures Fund ................................................................................ 8

Sponsors, Affiliate & Host ........................................................................................................9Sponsor ..............................................................................................................................................................10Nonprofit Affiliates .........................................................................................................................................11Organizer ..........................................................................................................................................................14BIO 2012, Boston ...........................................................................................................................................15

Presenter Profiles .................................................................................................................. 17About the Investor Pitches ..........................................................................................................................19Atentiv, Inc. .......................................................................................................................................................20BioDais, Inc. ......................................................................................................................................................22CytoCure, LLC ..................................................................................................................................................24Frontiera Therapeutics ..................................................................................................................................26HepatoChem ....................................................................................................................................................28Lumos Catheter Systems, Inc. .....................................................................................................................30NUChip ..............................................................................................................................................................32Photoral, Inc. ....................................................................................................................................................34Segterra ..............................................................................................................................................................36SIband, LLC .......................................................................................................................................................38SignaBlok, Inc. ..................................................................................................................................................40Targeted Cell Therapies, LLC .......................................................................................................................42TransCytos, LLC. ..............................................................................................................................................44Viridis Bio ...........................................................................................................................................................46Visus Technology ...........................................................................................................................................48VitaThreads .......................................................................................................................................................50

Additional Exhibitor Profiles .............................................................................................. 53Advirna ..............................................................................................................................................................54Binotech Laboratories, Inc. ..........................................................................................................................56ColdSteel Laser ................................................................................................................................................58Excellims Corporation ...................................................................................................................................60Massachusetts General Hospital ................................................................................................................62Nanocanary Technologies ..........................................................................................................................64Spordiff Therapeutics, Inc. ............................................................................................................................66Synthegenix Pharmaceuticals .....................................................................................................................67University of Massachusetts Medical School ..........................................................................................68ZS Genetics, Inc. ..............................................................................................................................................69


iv

April 12, 2012 Merck Research Laboratories ∙ Boston, MA

v

CONFERENCE AGENDA

12:45 – 1:15

Registration, Dessert Bar, Networking, and Exhibits

1:15 – 1:45 Welcome Panel “Rapid Funding Update”

Panelists:Richard Anders, Founder and Executive Director, MA Medical Angels (MA2)

Jeremy Halpern, Partner and Director of Business Development, Emerging Companies Group, Nutter McClennen & Fish LLP

Dr. Reid Leonard , Managing Director and Executive DirectorWorldwide Licensing & External Scientific Affairs, Merck Research Ventures Fund

Moderator:Abigail Barrow Founding Director, Massachusetts Technology Transfer Center

and Conference Chair

1:45 – 3:00 Company Pitch Presentations - Session One

3:00 – 3:30

Coffee Break

3:30 – 5:00 Company Pitch Presentations - Session Two

5:00 – 7:00 Networking Reception and Poster Session

April 12, 2012Merck Research Laboratories Laboratories ∙ Boston, MA

Biographies 7

Speaker Biography

Richard AndersFounder and Executive Director, MA Medical Angels (MA2)

Panelist

Richard Anders, is a lawyer turned entrepreneur. In 1984 he founded Jurisoft, which he later sold to Lexis/Nexis. He later was the publisher of Boston Digital Industry and New York Digital Industry, and currently is Managing Director of Rubin/Anders Scientific. Richard is a trustee of the Boston Museum of Science, a member of the MIT/Harvard Medical School HST program advisory council where he helps teach a course on the biomedical enterprise, and a trustee of the Boston Biomedical Research Institute. He is a member of the Institutional Review Board at the Dana Farber Cancer Center. He founded the angel groups Launch-pad and in 2008, MA Medical Angels (MA2), one of the country’s only angel groups focused exclusively on life sciences. Richard is a graduate Summa Cum Laude in mathematics from Harvard and holds a J.D. from Harvard Law School.

Abigail BarrowFounding Director, Massachusetts Technology Transfer Center and Conference Co-Chair

Panel Moderator

Abigail Barrow is the Founding Director of the Massachusetts Technology Transfer Center (MTTC). The MTTC is state funded and supports technology transfer activities from public and private research institu-tions to companies in Massachusetts. The Center works with technology transfer offices at all research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth. Prior to joining the MTTC, Dr. Barrow served as managing director of Wil-liam J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the Jacobs School of Engineering. Dr. Barrow worked in a variety of roles at UCSD CONNECT from 1990 to 2001. CONNECT’s programs focused on supporting early stage high-tech and biotech companies and in particular helping them raise funding from venture capitalists and corporate partners. Dr. Barrow has also worked with other regions where the CONNECT program has been successfully replicated, including Scotland and Scandi-navia. Dr. Barrow is a Fellow of UCSD’s Beyster Institute and an Xconomist for Xconomy.com.

Jeremy HalpernPartner and Director of Business Development, Emerging Companies Group, Nutter McClennen & Fish LLP

Panelist

Jeremy Halpern, is a Partner, and the Director of Business Development, Emerging Companies Group, at Nutter McClennen & Fish LLP, a Boston based law firm. As a former entrepreneur, Jeremy concentrates on connecting with and supporting the Entrepreneurial Ecosystem in New England, working with current entrepreneurs, angel investors, venture capitalists and corporate strategic partners.


8 Biographies

Concurrently, Jeremy serves on the Boards of The Capital Network, a Boston based non-profit serving en-trepreneurs, and the Massachusetts Technology Development Corporation, the venture capital arm of the Commonwealth. Jeremy is also a Professor of Entrepreneurial Leadership at Tufts University, a Connector in the Boston World Partnership, and a proud co-founder of Boston IDEA (a networking group for entrepreneurs in Boston’s Innovation District) and MassApps (a high speed business competition for the mobile software development community).

Previously, Jeremy was the Co-Founder and Executive Vice President of Business Development for Mo-bileTek Corporation, a developer of PC based applications enabling smarter mobility for consumer mobile devices. Prior to that, Jeremy ran a strategic consulting firm and practiced corporate law with other national law firms in Boston and Los Angeles.

Jeremy received his B.A., summa cum laude, Phi Beta Kappa, from the University of California, Berkeley, and his J.D. from the University of California at Los Angeles. Prior to law school, Jeremy spent two years as the Executive Chairman of a concert and special events production company.

Jeremy is a member of or participates at Launchpad Venture Group, Boston Harbor Angels, Golden Seeds, NE Angels, MassChallenge, Web Innovators Group, MassTLC, Mobile Mondays, Boston IDEA and Mas-sApps.

Dr. Reid LeonardManaging Director, Merck Research Ventures Fund

Executive Director, Worldwide Licensing & External Scientific Affairs

Panelist

Dr. Leonard is Executive Director, Worldwide Licensing for Merck and Managing Director of the Merck Re-search Ventures Fund. Based in Boston, Reid interacts regularly with biotechnology companies and aca-demic institutions to identify and evaluate partnership opportunities that will enhance Merck’s pipeline. A key component of this role is to maintain close contact with leading life science venture firms and other stake-holders in the New England innovation cluster. Reid also supervises scientific scouting for Canada, Latin America, and India.

Reid recently assumed the additional role of Managing Director of the Merck Research Venture Fund (MRVF), a strategic investment vehicle through which Merck will help to shape the diversity and quality of external innovation. In this capacity, Reid is responsible for the overall implementation and coordination of Merck’s in-vestments through the MRVF, working closely with colleagues from Merck Corporate Development, Finance, and External Scientific Affairs.

Prior to his career in business development, Dr. Leonard conducted basic research and drug discovery on ion channels at Merck. Reid is a graduate of Brandeis University, with a dual B.A. in biology and psychology. He earned a Ph.D. in biology (neuroscience) from Purdue University and completed postdoctoral training in molecular pharmacology at Caltech. Reid joined Merck Research Laboratories, Rahway NJ, in 1989 and spent ten years at the bench practicing drug discovery. In 1998, Reid moved into the External Scientific Affairs group where he has contributed to the search, evaluation, and execution of numerous biotech and academic partnerships to advance Merck’s pipeline.

Sponsors & Host 9


Sponsors, Affiliates & OrganizerSponsor ...................................................................................................................................... 10

Nutter McClennen & Fish LLP

Nonprofit Affiliates ................................................................................................................. 11Massachusetts Biotechnology CouncilMassChallengeMassachusetts Life Scences Center

Organizer .................................................................................................................................. 14The Massachusetts Technology Transfer Center

BIO 2012, Boston .................................................................................................................... 15

10 Sponsors & Host


Sponsor

Life Sciences Group

Helping businesses realize value from innovation. Nutter has a long track record of working with clients in the life sciences industry throughout the product and enterprise lifecycle. With an understanding of science and technology and a business savvy approach, our interdisciplinary team provides legal services in:

Capital raising and corporate finance IP strategy, prosecution and litigation Strategic collaborations and licensing Product liability Clinical trials and regulatory compliance Government investigations and defense Mergers and acquisitions

We represent a diverse international roster of life sciences clients, including:

U.S. and multinational medical device, biotech and pharmaceutical companies Renowned medical institutions and research universities Major hospitals and other health care providers Emerging growth companies Venture capital firms and Entrepreneurs

Partnering with clients to succeed.

Nutter McClennen & Fish LLPSeaport West, 155 Seaport Boulevard

Boston, MA 02210617.439.2000

www.nutter.com

Sponsors & Host 11


Non-profit affiliate

300 Technology Square, 8th Floor I Cambridge, MA 02139

TEL: 617.674.5100 I FAX: 617.674.5101 I www.massbio.org

12 Sponsors & Host



Global Startup Accelerator and Competition

What is MassChallenge?

MassChallenge is the largest-ever startup accelerator and competition, and the first to support high-impact, early-stage entrepreneurs with no strings attached. Benefits for startups include:

- 3-month accelerator program. World-class mentorship and training, free office space, access to funding, media and more.- $1M in Cash Awards. $4M+ in-kind support.- Open to all. Any startup can enter, from anywhere, in any industry.- No equity taken. No restrictions applied.

Results

MassChallenge 2010 Alumni raised more than $100M in capital and created more than 500 new jobs in under 12 months after joining MassChallenge.

President Obama honored MassChallenge in January of 2011 as one of the nation's best organizations for supporting high-growth entrepreneurs, and MassChallenge was the youngest inaugural member of the Startup America Partnership.

www.masschallenge.org

We help entrepreneurs win!

Sponsors & Host 13



14 Sponsors & Host


Organizer

[email protected]

www.MaTTCenter.org

www.MassTechPortal.org

The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachu-setts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

__________________________________________________________________________________

The Center: facilitates and accelerates technology transfer between research institutions and Massa-• chusetts companies;promotes collaboration between research institutions and the Commonwealth’s technol-• ogy industry; assists in the growth of Massachusetts companies, including startups, by enhancing tech-• nological leadership; andsupports regional and statewide economic development priorities. •

__________________________________________________________________________________

The Center supports the commercialization of research technologies through a variety of programs:

The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.

Commercialization and Entrepreneurial Education seminars and workshops enable researchers to un-derstand the process of commercializing technologies.

Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.

Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.

Sponsors & Host 15


What’s Your

BIO is where you connect with 15,500 business leaders from 65 countries. Find global partners to fund, sustain and advance projects. Stay abreast of the issues shaping the industry. Identify innovations to move your technology forward. It’s all of these objectives and more, all to help you make the most of your BIO.

It’s what you can make happen at BIOTECH’S BIGGEST EVENT.

ReGister today for Full Convention Access & PartnerinG at convention.bio.orG

Follow us:

CONNECT. PARTNER. INNOVATE .

June 18 – 21, 2012 Boston, MA

8493 BIO12_MASTER AD_GENERICBW_LST.indd 1 3/5/12 3:37 PM

16 Sponsors & Host



Startup Companies 17

Presenter ProfilesAbout the Investor Pitches .................................................................................................. 19Atentiv, Inc. ............................................................................................................................... 20

Eric B. Gordon, CEO and Founder

BioDais, Inc. .............................................................................................................................. 22James Coon, President and CEO

CytoCure, LLC .......................................................................................................................... 24James T Kurnick, Managing Partner

Frontiera Therapeutics .......................................................................................................... 26Usamah S. Kayyali, Associate Professor of Medicine, Tufts Medical Center

HepatoChem ............................................................................................................................ 28Marc Bazin, President

Lumos Catheter Systems, Inc. ............................................................................................. 30Farhad Imam, President, Chief Medical Officer

NUChip ...................................................................................................................................... 32Asanterabi Malima, CEO

Photoral, Inc. ............................................................................................................................ 34Stamatis N. Astra, President & CEO

Segterra ...................................................................................................................................... 36Gil Blander, President, Founder, and CSO

SIband, LLC ............................................................................................................................... 38George Kenney, President

SignaBlok, Inc. .......................................................................................................................... 40Alexander B. Sigalov, President and Founder

Targeted Cell Therapies, LLC ............................................................................................... 42Edward I. Ginns, President and CEO

TransCytos, LLC. ...................................................................................................................... 44Otto Prohaska, CEO and Co-Founder

Viridis Bio ................................................................................................................................... 46Leo E. Otterbein, Founder

Visus Technology .................................................................................................................... 48John Wyatt, Founder

VitaThreads ............................................................................................................................... 50Glenn Gaudette, Founder


18 Startup Companies



About the Investor Pitches

IntroductionThe Massachusetts Technology Transfer Center hosts several conferences a year, each to showcase early stage entrepreneurs in a different technology or industry sector. The heart of each showcase is the ten-minute investor pitches given by selected entrepreneurs followed by a reception in an exhibit hall at which interested attendees can meet the entrepreneurs and network with other participants.

The pool of applicants to present has grown since our inaugural conference in 2005, so we have selected as broad a range as possible, from technologies still in the university laboratory to companies starting to sell product; from the most polished and experienced presenters to those who have never presented to the business community before; from the most cutting edge technology to established technologies that still support an innovative business model.

Business and Technology MaturityThe mandate of the MTTC is to help entrepreneurs based in Massachusetts nonprofit research institutions to commercialize their technologies. Thus, we always give priority to applicants from our hospitals and universities. However, we are also working toward economic development in the state, so we welcome entrepreneurs already working in startup companies, giving preference to those who are collaborating. Those who have already received significant venture capital are beyond the scope of this section of the conference.

Some presenters are alumni of prior Conferences. They are invited to participate only if they have signifi-cant business updates to incorporate into their investor presentation.

MTTC CoachingEach presenter participates in a coaching session prior to the Conference to ensure that no pitch is longer than ten minutes and that each contains critical business information along with high-level data on the technology. Our purpose is to provide investors in the audience with a time-efficient opportunity to learn of the latest technologies being made available for commercialization and to be able to evaluate their busi-ness potential at a preliminary level.



Atentiv, Inc.Presented by:Eric B. Gordon, CEO and Founder

Company overviewAtentiv provides personalized digital learning tools to children and adults that naturally optimize remediate or rehabilitate inattention, poor working memory and other learning disorders. The Atentiv™ System uses a real-time, proprietary, easy to use, direct brain-to-computer in-terface technology to measure in minutes the precise discriminating EEG features through a range of attention levels for each user. The technology platform produces product applications that enable rapid, precise non-invasive objective assessments, customized training, man-agement and genuine demonstration of newly acquired learning skills. Additional product applications aimed at deferring Alzheimer’s disease for 5-10 years and minimizing sleep insomnia are now under develop-ment by the licensor, which Atentiv has sole commercial rights.

Product/Technology ProfileEveryone’s brain is a continuous naturally evolving structure throughout a lifetime that enables a lifelong learning process of continual activation of electrical impulses that bind neurons together through a synapse. A person’s repeated actions to learn and experience new activities (i.e., ‘direct functional challenge’) causes learning neurons to sense other neurons, extend dendrites to meet axons, and create new brain struc-tures and therefore new skills, such as attention, working memory, ab-stract reasoning and other essential executive functions. The longer and the more frequently those neurons send and receive impulses the stronger and more enduring the linkage, therefore the stronger and more enduring the targeted brain function.

The Atentiv™ System uses a real-time, proprietary, EEG-based, direct brain-to-computer interface technol-ogy to identify unique discriminators of attention and measure the range of attention levels of the user to establish a personal cognitive signature or a customized range of discriminating attention biomarkers. Using the personalized cognitive signature, product applications enable rapid, precise non-invasive objective as-sessments of attention levels in real-time during a direct functional challenge to a targeted executive function, such as attention or working memory. Correspondingly, highly engaging personal training programs (virtual 3D games) are adaptively developed in real-time to play back to the user and maximize enduring neuronal linkages in the brain. Applications provide practical and personal management of success and genuine dem-onstration of newly acquired learning skills. Additional product applications are now under development.

Market and ApplicationPoor learning skills impair the lives of tens of millions of people, as many as 1 in 8 children and 1 in 12 adults, which lead to serious lifelong consequences and missed opportunities for individuals and their fami-

Officers and Directors:Eric B. Gordon, Chairman, CEO, and PresidentRobert Taber, BODJoe Grace, VP Consumer Mar-ketingJohn Hope, VP Educational MarketingJohn Shambroom, VP Technol-ogyJeremy Soybel, VP Information and Communications

Contact Information:Eric B. Gordon245 First St. 14th FloorCambridge, MA 02142Phone: [email protected]



lies. Moreover, because of a global lack of awareness and objective diagnostics, learning disorders, such as ADHD, are significantly under diagnosed and under treated. Current treatments, both drug and non-drug therapies, may mitigate certain symptoms but do not treat the disorder itself. Efficacy of drug therapy is in-consistent, of short duration and may incur severe negative side effects and stigma aside from known abuse risks. Direct costs for managing these mental disorders by school systems and health care providers are tens of $ billions while negative impacts on family, productivity and necessary remedial actions push global costs to hundreds of $billions. Global 2011 ADHD stimulant revenues were ~$7.2B of which ~$5.3B were in the U.S.

Commercial Opportunity There are multiple markets focused on meeting the global demand to optimize learning skills and remediate or rehabilitate learning disorders. These include:

1. K-16 Education- School systems are now radically reshaping their curriculum to concentrate first on maximizing 21st Century learning skills. Children and their parents are highly motivated to optimize education for their child.

2. Attention Deficit Hyperactivity Disorder (ADHD) Remediation – Children and their parents and adults are desperately searching for genuine non drug solutions, which have no side effects and are effec-tive for sustained periods of months to years.

3. Peak Performance – Employers, individuals, athletes and military are seeking simple, self adminis-tered brain health and fitness games to maximize individual performance and productivity.

4. Wellness - Healthcare providers, payers and industry are interested in maximizing attention, working memory and other cognitive skill performance to optimize personal health for significant cost reduc-tions and benefits.

Competitive AdvantagesA cottage industry of early innovators with various technological approaches for multiple ‘brain health and fitness’ applications has rapidly emerged. These first generation ‘brain feedback companies’ offer a variety of computerized assessments, brain fitness therapies, training and related services for cognitive skill develop-ment. In the US, these companies had cumulative 2010 revenues ~$500M (CAGR of >30%) at which pace places 2015 at a~$2B US Market and global markets at ~$4B. However, commercialized ‘brain health and fitness’ applications, often referred to as ‘brain feedback systems’, are often ineffective in optimizing learning skills to achieve normalized levels because they are unable to precisely target, objectively measure, train and manage actual brain function to desired outcomes. In addition, competitive products are difficult to use in the home, classroom or work and, as a result, suffer from poor compliance. However, the Atentiv™ System is not only simple and fun but provides critical features at a fraction of annual deductible costs while uniquely illustrating to the user their newly developed attention skills. The Atentiv™ System is not a brain feedback system.

Future Financial Plans

To date, technology, intellectual property and product development has been funded by A*STAR and the Founder. $6 million of capital to complete scale up from the validated functional prototype to full ‘launch-ready product applications’ is now being raised with a select group of savvy and sophisticated investors who are committed to breakthrough learning skill technologies and mental healthcare. Clinical studies for FDA clearance of an ADHD treatment indication have been funded by non dilutive grants and an additional $3M of non dilutive grants is expected to fund three more studies in 2012 and 2013. An additional $6-8M for product launches in 2013 and 2014 is expected to be raised from a combination of strategic marketing partners, sub-licensees, local loan facilities, grants and possibly new or the same investors. A Subscription Agreement and Term Sheet are available at the Company for Accredited Investors interested in investing in Atentiv, Inc.



BioDais, Inc.Presented by:James Coon, President and CEO

Company Overview BioDais was founded to provide a bridge between the basic, academic research ongoing in Dr. Kevin Kit Parker’s laboratory at Harvard Univer-sity and industry partners interested in the application of the research to drug discovery and regenerative medicine.

We take a cell to tissue scaling approach in building and adapting the Company’s in vitro systems to mimic normal and disease human physi-ology. We build our in vitro systems by understanding the whole or-gan, tissue architecture, and the cellular microenvironment in normal healthy, disease, and injured tissues, to build more predictive, human relevant assays and tools.

BioDais specializes in the characterization of ES and iPS-derived cell lines, establishing functional quality control parameters and providing custom, bioengineered solutions that that have been demonstrated to “push” stem cells to a more adult, mature phenotype that is more in vivo relevant for drug development and regenerative medicine applica-tions.

BioDais is utilizing the proprietary muscle thin film (MTF) technology developed in Dr. Parker’s laboratory to model cardiac function, disease, efficacy, and toxicity in a predictive in vitro system that recapitulates the human heart microenvironment and tissue architecture.

Product/Technology ProfileBioDais is applying the company’s bioengineering and cell biology expertise to characterize the functional and developmental state of ES and iPS-derived stem cells in order to design custom platforms that can im-prove the maturation, differentiation and function of stem cells for drug discovery and regenerative medicine applications.

BioDais is using its muscle thin film technology to provide a model of human cardiac function, disease, ef-ficacy and toxicity. The model is capable of providing engineered tissues from different regions of the heart, as well as, the ability to perform mechanistic studies that can be scaled to better predict animal or human studies.

BioDais has built brain specific microenvironments that can be adapted to mimic normal, injured and dis-eased brain tissue. Leveraging custom instrumentation, BioDais is able to recapitulate a traumatic brain injury in an in vitro system allowing mechanistic studies and screening of therapeutic interventions.

Officers and Directors:James Coon, President and CEODr. Kevin Kit Parker, Harvard University, SEAS, DBG

Contact Information:Coon, JamesPresident and CEOBioDais, Inc.125 Western Ave.Harvard Innovation LabAllston, MA 02163Phone: 617-838-1339Fax: [email protected]



Market and ApplicationBioDais is seeking to utilize its proprietary technology and resulting in vitro models and tools/devices to build a contract research business focused on meeting the needs of two distinct market opportunities:

1) BioDais will be working with pharmaceutical companies to address the need for more human relevant and predictive in vitro models.

2) BioDais will work with stem cell and regenerative medicine companies to characterize stem cells and then design new, proprietary in vitro systems to address shortfalls in function and utility.

Commercial Opportunity BioDais is in discussions with several pharmaceutical companies and expects to begin generating revenue, for in vitro efficacy and safety studies, by May 2012. BioDais is also in discussions with several leading stem cell providers to establish contract service revenue, for stem cell characterization studies, that will lead to larger model development contracts. In addition to revenue, these larger contracts will result in the develop-ment of proprietary in vitro systems that will provide additional intellectual property and licensing opportuni-ties for BioDais.

Competitive AdvantagesBioDais’ in vitro models can recapitulate normal and disease physiology better than existing in vitro models currently being employed and are readily adaptable to a diverse number of experimental formats, organ sys-tems, disease states and experimental endpoints.

BioDais’ ability to systematically characterize the functional shortfalls of human derived stem cells and then address these shortfalls with novel, proprietary in vitro systems is currently unique in the industry.

To maintain its competitive advantage, BioDais will be rapidly moving into other muscular organs, as well as the brain. BioDais will also leverage the Founder’s extensive professional networks, Dr. Parker’s scientific prominence and Mr. Coon’s history of success with in vitro businesses.

Future Financial PlansBioDais is seeking to predominately grow the business organically from contract service revenue and SBIR/STTR grant funding. However, given the number of near-term market opportunities that BioDais has identi-fied, we are considering seeking initial start-up investment that would position BioDais to rapidly grow its contract research business, develop new models and position the company for strategic partnerships and an eventual exit. Initial investment would be utilized to expedite formalizing operations, establishing laboratory facilities, hiring of key personnel and the purchase of capital equipment.



CytoCure, LLC Presented by:James T Kurnick, Managing Partner

Company OverviewCytoCure LLC is an early-stage biopharmaceutical company founded on a novel platform technology to develop anti-cancer drugs that will make therapeutic cancer vaccines more effective. When combined with cancer immunotherapy, CytoCure’s drugs will enhance patients’ ability to recognize and destroy their own malignant tumors.

CytoCure scientists have discovered a process by which tumor cells lose expression of genes encoding immune targets. This process of “antigen silencing” is a common finding among tumors. CytoCure sci-entists have shown that the loss of these antigens is often due to re-versible gene regulation. Proprietary CytoCure technology is based on overcoming tumor-produced factors that induce loss of tumor antigens, thus assuring that the tumor cells continue to express the antigenic structures that will allow the immune response to destroy all tumor cells in the tumor mass.

CytoCure’s research has been funded privately and by approximately $1 million in SBIR grants from National Institutes of Health (NIH). The NIH grants have funded the background work for the up-regulation of antigen expression by Interferon-beta, and additional development grants to fund work for high throughput screening of antigen up-regulating compounds and to characterize the mechanisms controlling antigen expression.

Facilities: CytoCure’s laboratory facilities and administrative office are located in Beverly, Massachusetts. The laboratory facilities incorporate a full service tissue culture as well as a dedicated molecular biology laboratory. The company maintains state of the art flow cytometry instrumentation as well as equipment for protein and molecular biological assays.

Product/Technology Profile Since the loss of tumor associated antigens currently represents a significant limitation to the success of cancer vaccines, the re-introduction and/or up-regulation of antigen expression will be a necessary adjunct to these therapies. Although the anti-tumor immune response can be markedly enhanced by strategic vaccina-tion, the ability to destroy the tumor is dependent on the continued expression of the target antigen. CytoCure’s technology provides for a platform to assure the continued expression and regulation of “antigen silencing” to enhance immunotherapeutic treatment of cancer.

The cancer therapies envisioned by CytoCure’s first-line of therapeutics will require combining two compo-nents:

(1) The antigen augmentation drug (i.e. a drug that increases antigen expression) which CytoCure has developed and identified; and

(2) An Immunotherapeutic Intervention, such as adoptive immunotherapy. To date, CytoCure has identi-fied biologically available small molecule leads and the cytokine, interferon-beta, that is already ap-proved for the treatment of Multiple Sclerosis, and has produced tumor-specific cells that can be used in immunotherapy.

Officers and Directors:James T. Kurnick, Managing Partner Paul J. Durda, President and Co-founderLenora Rose, CFO and Co-Founder

Contact Information:CytoCure, LLC100 Cummings Ctr. Suite 430CBeverly, MA 01915Phone: 781-799-6629Fax: 815 642 [email protected]



CytoCure has been granted a U.S. and Australian patent and in May of 2011, CytoCure submitted additional patent applications Combining Immunotherapy and Tumor-Antigen Induction in Human Melanoma.

To fast track CytoCure’s first therapeutic product the company has formed strategic alliances to implement a combination immunotherapy clinical trial that will use Interferon-beta to enhance expression of the tumor an-tigens on the malignant melanoma cells in vivo. A consortium of major academic medical centers in Australia has agreed to provide patients and laboratory assessment facilitites for this combination immunotherapy / interferon-beta trial in melanoma. This clinical trial will qualify for approval by the United States Food and Drug Administration (US-FDA).

Market and ApplicationThe Malignant Melanoma Market Place

Because of its resistance to conventional therapy, novel therapeutics represent the best hope for patients with advanced disease. During the 20th century, the incidence of melanoma rose at an alarming rate. Each year, approximately 80,000 people were diagnosed in the seven major pharmaceutical markets. Australia and New Zealand have by far the world’s highest incidence of malignant melanoma. Factors influencing pharmaceutical sales will include the increase in malignant melanoma incidence, a trend toward more ag-gressive treatment of the disease, and combined drug and immunotherapy products such as those being developed by CytoCure. Health expenditures on melanoma in the United States alone are soon expected to exceed US $5 billion, with major expenditures on patients whose disease cannot be controlled by currently available therapies. Although initial implementation of therapies will likely focus on patients with demon-strated metastatic disease, the prospective treatment of patients with no demonstrable disease as prophy-laxis against recurrence could expand the targeted population exponentially. If approved for the treatment of melanoma, this combination therapy could qualify for “orphan” drug status for treatment of diseases with less than 200,000 cases per year, providing an exclusive market for 7 years in the United States. The European Union has also developed an orphan drug program for treatment of diseases that affect less than 5 in 10,000 population.

Beyond Melanoma

Therapies of Additional Tumors: While the initial studies by CytoCure scientists have focused primarily on malignant melanoma, CytoCure has evidence that other tumor types will similarly turn off the expression of their antigens. Cancers such as renal cell carcinomas have also proved amenable to active immunothera-peutic intervention. Furthermore, a wide variety of tumor antigens expressed in cancers of the breast, colon, prostate, ovary, uterus, stomach, pancreas, lung, brain as well as lymphomas and leukemias, have been described which can be used as targets of active immunotherapy if the expression of these antigens can be assured and enhanced. Some of the same antigens that are targeted in melanoma are also expressed on brain tumors, and CytoCure’s studies indicate that brain tumor cells are likewise able to enhance antigen expression in response to many of the same agents that CytoCure has shown are active in malignant mela-noma.

Future Financial PlansCytoCure has a submitted SBIR funding to allow animal studies to test in vivo efficacy of Hsp90 inhibitors in combination with immunotherapy of melanoma. This application has been reviewed and received a very high priority score (score of 20, which is in the top 10% of all applications reviewed), and is awaiting this award to allow more aggressive animal testing for proof of concept in vivo.

Cytocure is seeking additional funding to allow completion of the animal studies and to begin clinical trials in humans. With the Australian collaborators, the cost of a proof of concept trial can be undertaken with ap-proximately $2 million. If the preliminary clinical trial data prove effective, a larger trial would be undertaken towards FDA approval of a therapeutic combination immunotherapy. These expanded clinical studies would require substantial financial input.



Frontiera TherapeuticsPresented by:Usamah S. Kayyali, Associate Professor of Medicine, Tufts Medical Center

Company OverviewFrontiera Therapeutics is a startup company that focuses on drugs to treat vascular diseases related to increased permeability and edema. The first product to be developed is MK2-AP, an activator of the en-zyme MK2, which causes increased phosphorylation of the small heat shock protein, HSP27.

MK2-AP has shown effectiveness against anthrax toxin-induced vascu-lar leak and pulmonary edema in cell culture and animal models. This drug is expected to be of great benefit to anthrax patients as well as to patients suffering from Acute Lung Injury (ALI) due to other agents ranging from influenza to sepsis. Currently Frontiera is testing the ef-fectiveness of MK2-AP in sepsis animal models.

There is a great unmet need for treatment of ALI, which is fatal in 35-50% of cases. Despite numerous randomized clinical trials, the only therapy is a protective ventilation strategy. ALI represents a $1.8 billion market opportunity in the US alone. MK2-AP compositions are under a provisional patent application filed by Tufts Medical Center.

Founder Usamah Kayyali has 15 years of experience being independently funded by NIH, DoD, State and National Foundations. Dr. Kayyali’s work has been published in numerous peer-reviewed journals and he has an extensive background in collaborating with industry.

Product/Technology ProfileFrontiera has shown that p38 MAP kinase activation and phosphorylation of its substrate kinase, MK2, and the latter’s substrate, HSP27 leads to barrier augmentation. Recently we have published that the ability of anthrax lethal toxin (LeTx) to inhibit p38-MK2-HSP27 signaling can be specifically linked to its ability to weaken the endothelial permeability barrier.

The first product to be developed is MK2-AP, an activator of the enzyme MK2, which causes increased phosphorylation of the small heat shock protein, HSP27 leading to augmentation of the permeability barrier. MK2-AP has shown effectiveness against anthrax toxin-induced vascular leak and pulmonary edema in cell culture and animal models. This drug is expected to be of great benefit to anthrax patients as well as to pa-tients suffering from ALI due to other agents ranging from influenza to sepsis. Currently Frontiera is testing the effectiveness of MK2-AP in sepsis animal models.

A unique aspect of our targeting the endothelial permeability effect is the focus on barrier augmentation. Most permeability research has focused on the signaling pathways activated by permeability-inducing agents that weaken the barrier and increase permeability. In addition, using a novel approach Frontiera has developed a kinase activator, whereas most companies have focused on kinase inhibitors.

Officers and Directors:Usamah S. Kayyali, Associate Pro-fessor of Medicine

Contact Information:Tufts Medical CenterTufts University School of Medi-cine800 Washington Street, #257Boston, MA 02111Phone: 617) 636-4352Fax: (617) [email protected]://160.109.101.132/Pulmo-nary/Faculty/UsamahKayyali.asp

Frontiera

Therapeutics



Market and ApplicationALI occurs in 200,000 patients annually and has an estimated mortality rate of 40%. Within intensive care units, approximately 10-15% of admitted patients meet criteria for ALI. The unmet need of the ALI market is high as there are no approved drugs currently on the market.

More than 60 possible causes of ALI have been identified and other potential causes continue to emerge. However, only a few common causes account for most cases of ALI including sepsis, aspiration, pneumonia, and severe trauma. Sepsis is the most common cause of ALI, accounting for up to 74% cases.

ALI represents a $1.8 billion market opportunity in the US alone. Frontiera is seeking orphan drug status for MK2-AP.

Commercial Opportunity Frontiera aims to develop first in class peptide therapeutics towards ALI:

1. Initially validate drug candidates in animal model of ALI and progress to proof of concept clinical trial in humans

2. Seek appropriate funding (public and/or private) to achieve goal (1)3. Secure strategic partner to advance lead candidate through pivotal clinical trials, regulatory approval,

and eventual market distribution

Competitive AdvantagesDespite numerous randomized clinical trials, the only therapy for ALI is a protective ventilation strategy. Potential ALI-specific therapies have been studied; however, they have not been shown to improve clinical outcome. Several companies are involved in ALI therapeutic development including Faron Pharmaceutical and Discovery Laboratories. However, Frontiera has a unique approach to targeting endothelial permeability by focusing on barrier augmentation. MK2-AP compositions are under a provisional patent application filed by Tufts Medical Center.


Yr1 Yr2 Yr3 Yr4 Yr5

Product Development1. Identification of optimum dose and regimen of MK2-AP to protect against LeTx-induced vascular leak in rats2. Determination of ability of MK2-AP to protect against LPS-induced vascular leak in rats3. Performance of preclinical studies on MK2-AP

4. Conducting AMD analysis and pharmacokinetic PK studies; develop manufacturing5. Preparation of investigative new drug submission for advancement into clinical trials

Personnel

Supplies

Total $226K $237K $510K $510K $510K

1. Employees including Principal Investigator, Collaborator, and Research Associates

1. Supplies including tissue culture materials, antibodies and immune reagents, and general lab supplies

$101K

$239K

$245K

$245K

$94K

$114K

$219K$226K

$110K

$232K

$22K

$52K

$39K

$22K

$32K



HepatoChem

Presented by:Marc Bazin, President

Company Overview, Product, and Market

HepatoChem (www.Hepatochem.com) is an emerging but revenue-generating company dedicated to the commercialization of a novel type of chemistry, based on the use of metallo-porphyrins. The first commercial application selected by the company is metabolite profiling & production from bioactive small molecules. Indeed, HepatoChem has developed a unique solution to resolve the lack of metabolite access in drug discovery. HepatoChem is already providing reliable metabolite services to the bio-pharma industry in exchange for a fee and plans to expand the service to the food industry in the near future.

The ultimate objective however, is to re-invest the cash flows from the fee-for-service business to develop innovative (i.e. difficult to synthe-size) proprietary small molecules for the drug industry, thanks to the unique chemical reactions allowed by porphyrins and other catalysts. HepatoChem will also provide drug companies the opportunities to re-duce the cost of goods of their small molecules. The business oppor-tunity can be described in two parts: i) A service business on oxidative stress across the three main applications of metabolite production, food additives and chemical degradation, ii) A Drug Discovery business for active metabolites, natural compounds and lead generation.

Early access to substantial quantities of metabolites in the discovery phase is becoming increasingly impor-tant as it enables faster and better decisions to determine whether a drug candidate merits further develop-ment. Identification of metabolic or toxicity issues early in the drug development process is critical for the drug industry and it translates into significant savings. Moreover, the FDA issued a new guidance for regula-tory approval in 2008 that now requires systematic safety testing of drug metabolites.

Developed in collaboration with Prof. John Groves at Princeton University (www.princeton.edu/chemistry/faculty/profiles/groves/), this novel chemistry mimics the metabolic function of any animal livers, including humans. This platform combines the advantages of both bio-catalysis and organic chemistry and provides the efficiency and scalability demanded by the current drug discovery players.

Fast access to mg quantities of metabolite in a couple of weeks impacts drug discovery by enabling the quantification, identification, evaluation and safety studies of metabolites as well as the optimization of their pharmacokinetic properties

As a Base Business, HepatoChem wants to become the leader for metabolite production. “Go to market” will be achieved directly with a small sales force and indirectly through specialized distributors like, Cerep and other chemistry CROs, within and outside the US. In order to retain full control, HepatoChem does not plan to transfer the technology, at least until the next business application has reached commercialization stage (i.e. synthesis of complex/natural compounds and COGS reduction directly). The objective of HepatoChem is to reach at least 10% penetration in this market by 2016 or a minimum of $10M in revenue, which would

Officers and Directors:Marc Bazin, Presidentand Co-Founder.John T. Groves, Vice-President, Co-Founder and board directorJean-Marie Vallet, Board direc-tor, Acting CBO Ryan Buzdygon, Project Man-agerShelley Amster, Business Devel-opment ManagerMarie Landel, Acting Treasurer & CFO

Contact Information:100 Cummings Center Suite 424JBeverly, MA 01915Phone: 857 998 [email protected]



translate into a company valuation in the $25-30 million range, just from marketing the metabolite service business to the US based drug industry, 70% of which is constituted by small molecules.

As of December 5th, the 2011 revenue projections are $90K for the trailing 12 months and we anticipate sig-nificant growth in the next two years. Based on the current market demand for metabolite services, driven in part by the latest FDA Guidelines and on the other hand, by the intense desire of drug developers to reduce economic waste and drug candidate attrition, we do not anticipate regulatory or scientific risks. Thanks to our close business relationship with the inventor of platform, we do not anticipate any serious competitive or intellectual property risks either. Instead, we believe the only risk faced by our company has to do with management and execution of the commercial plan.

HepatoChem, Inc. (a Delaware corporation) was founded in August of 2008. Since then we have validated our technology and began to promote our Metabolite Production Service. We signed our first contract in 2009 followed by several contracts in 2010. HepatoChem is part of the NorthShore Biotech InnoVenture Center since 2010. We relocated to Beverly, MA from Princeton University in June 2011. During 2011, we hired our first full time employee, as well as two part time professionals in business development. We are now in dis-cussion with more than 15 pharmaceutical companies and in active partnership discussions with chemistry CROs.

Future Financial Plans HepatoChem is seeking an additional funding to complete its Series A ($300K)



Lumos Catheter Systems, Inc.

Presented by:Farhad Imam, President, Chief Medical Officer

Company OverviewLumos Catheter Systems has developed a real-time visualization sys-tem to reduce the risk of misplacement during invasive catheter in-sertion procedures (e.g., peripherally inserted central catheters, or “PICC”). By channeling visible light to the catheter end via novel fiber optics, Lumos provides the clinician with continuous real-time informa-tion on catheter location that is easily seen with the naked eye and simple enough to be used independently at the bedside. Patients, clini-cians and hospitals will benefit from this safer, faster and less costly method of catheter insertion.

Team:

Farhad Imam, M.D., Ph.D. – President and Chief Medical Officer. Dr. Imam is a neonatal intensive care physician at Children’s Hospital Bos-ton, a Clinical Instructor in Pediatrics at Harvard Medical School, and is the sole inventor on all patents pertaining to the transilluminating catheter. He has raised $440,000 from governmental and academic sources thus far to develop and optimize the transilluminating catheter. Dr. Imam has served as a medical device consultant for VueTek Scientific, in addition to having published multiple scientific research papers.

Tim Robinson – Vice President of Research and Development. Mr. Robinson has over 20 years of experi-ence in the design and development of intravascular and optical catheters. He has held key roles in engi-neering and research at C.R. Bard, TDC Medical, Seacoast Technologies, and Implemed.

Keith Bonin, Ph.D. – Biophotonics consultant. Dr. Bonin is Professor and Chair of the Department of Physics at Wake Forest University and has consulted for multiple medical and optical device companies over his 30-year academic career in solid-state physics. He heads a research laboratory with multiple NIH grants focus-ing on the use of light in biological tissue for diagnosis and treatment of cancer and other diseases.

Ian Edvalson, J.D. – Legal Counsel. Mr. Edvalson is a partner in Wilson Sonsini Goodrich & Rosati. He rep-resents clients in domestic and international transactions involving intellectual property or product rights with specific domain expertise in medical technologies. Prior to rejoining WSGR in 2002, Mr. Edvalson was senior vice president of corporate and business development at Third Wave Technologies, Inc.

Product/Technology ProfileLumos uses fiber optic technology to provide real-time visualization of catheters during insertion procedures. The traditional stylet used to give catheters stiffness during insertion procedures is replaced with the Lumos optical fiber stylet. An LED light source is coupled to the proximal end of the fiber optic. The light travels down the length of the fiber and is released through specific emission windows designed into the optical fiber itself. Light exiting the fiber optic transilluminates visibly through the catheter and patient tissue, providing

Officers and Directors:Farhad Imam, President, CMOTim Robinson, VP of Research and DevelopmentKeith Bonin, Biophotonics Con-sultantIan Edvalson, Legal Counsel

Contact Information:50 Saint Paul St #5Brookline, MA 02446Phone: 617-368-0484Fax: [email protected]://www.lumoscathetersys-tems.com/



the clinician with real time information on catheter tip location. Lumos has optimized the emitted wavelengths to robustly and visibly transilluminate living tissue, and has rights to the patent family describing the transil-luminating catheter from Children’s Hospital Boston. To date, our technology has been demonstrated suc-cessfully in a live rabbit and pig model using a range of animal sizes that approximates neonates, pediatric patients, and adults. A detailed in vivo efficacy and safety study is to be performed using a sheep model in early April at a local animal research facility with the definitive prototype device in preparation for a focused human study to follow.

Market

PICC catheters are a ubiquitous tool used worldwide to allow patients to more safely and conveniently receive strong medicines, concentrated nutrition and/or long-term intravenous fluids. An estimated 1.5 million PICCs are placed annually in the United States (US) alone. Demographic trends and product improvements have driven both PICC usage (10.3% annual growth, 2007) and average sales price (approximately $130 per PICC). The US PICC market is estimated to be $280M (2009).

PICC insertion procedures are fraught with risk. Once the tip penetrates the skin, the medical professional relies only on feel and a distance metric to judge placement. In the elderly, neonates and chronically ill, studies reveal a failure rate for proper tip location of up to 85% on first attempt. Indeed, errant PICC placement can result in serious consequences including tissue/organ damage and cardiac arrhythmia.

As with PICC lines, similar guidance problems exist for other invasive access products such as chest tubes, nasogastric tubes, umbilical catheters and endotracheal tubes and represent future growth opportunities for Lumos.

Commercial Opportunity and Competitive Advantages

PICC pricing has proven to be elastic over the past several years as hospitals and physicians have readily accepted higher prices for incremental improvements in catheter performance. We believe customers will similarly accept price increases in exchange for the cost and safety benefits of Lumos technology.

Four products are in use today: (a) fluoroscopy in the surgical suite, which is the gold standard, (b) a com-bined EKG-magnetic approach from C.R. Bard, and an EKG-doppler approach from VasoNova. One addi-tional product may launch within the coming years using an infrared light strategy from LumenVu/Sonosite. None of these strategies, however, specifically target nor are as well suited for the neonatal and young pe-diatric market as the Lumos Catheter System with visible transillumination. In addition, only Lumos provides real-time bedside visualization of the internal course of the catheter to the practitioner, providing instanta-neous, direct feedback.

Future Financial Plans Lumos currently seeks series A financing of $1.3MM to fund a focused human trial, to obtain FDA approval via the 510(k) pathway, and to continue to develop and secure the IP portfolio. Lumos intends to seek part-nership and/or acquisition from a major PICC manufacturer upon achievement of 510(k) approval.



NUChip

Presented by: Asanterabi Malima, CEO

Company Overview NUChip is a multi-biosensor diagnostic company with a vision to create a revolution in the diagnostic and point-of-care industry by improving the health of people suffering from cancer and other diseases. Our state-of-the-art technology combines standard semiconductor fabrica-tion techniques with nanotechnology, resulting in a unique micron-scale biosensor for simultaneous detection of multiple biomarkers.

The NUChip allows simultaneous detection of small amounts of dif-ferent proteins of interest using conventional enzyme-linked immu-nosorbent assay (ELISA) technique, in small sample volume making detection highly sensitive and versatile. High- throughput screening of multiple diseases, drug-discovery and low cost are some of the other features of this device.

Management backgrounds:

Asanterabi Malima is a Ph.D. candidate in Electrical and Computer Engineering. His tasks are macro-assem-bly, fabrication and micro-assembly of the biosensors.

Jaydev R. Upponi received his Ph.D. in Pharmaceutical Sciences. His expertise is antibody immobilization and functionalization of polystyrene nanoparticles.

Cihan Yilmaz, is a Ph.D. candidate in Mechanical Engineering. His research focus is directed assembly of nanoparticles for electronics, optics and biosensing applications.

Product/Technology Profile NUChip is a highly sensitive multiple biomarker biosensor device that is used for detection of low levels of various cancer biomarkers in biological fluids. This biosensor is capable of detecting multiple biomarkers at a given time with minimal false positives. This enables early detection, thereby allowing early treatment of a de-veloping cancer. NUChip can also assist physicians to monitor cancer patients during and after treatment.

According to recent National Cancer Institute (NCI) statistics, the survival rate of cancer patients such as prostate cancer increases up to 100% if the cancer is detected at an early stage. The current diagnostic methods for cancer are not capable of detecting low concentration of biomarkers. Additionally, these meth-ods do not detect multiple biomarkers simultaneously making early detection extremely difficult. This in turn leads to use of labor-intensive and costly equipments such as MRI (Magnetic Resonance Imaging), CT (Computed Tomography) scan, etc for detecting cancers.

NUChip enables early detection of cancer diseases at low-cost, thereby significantly increasing the survival rate of the patients while decreasing the cost involved in detection and treatment processes.

Officers and Directors:Asanterabi Malima, CEOJaydev R. Upponi Cihan Yilmaz

Contact Information:327 Huntington Avenue, No. 9

Boston, MA 02115Phone: [email protected]



Market and Application

Our target market is cancer diagnostics. The National Institutes of Health (NIH) estimates that the overall costs of cancer in 2007 was $226.8 billion: $103.8 billion for direct medical costs (total of all health expenditures) and $123.0 billion for indirect mortality costs (cost of lost productivity due to premature death). In 2020, 16 million new cases of cancer are expected, and cancer deaths are projected to reach 10 million. According to NIH the projected cost in 2020 would increase by 27% to that of 2010. Use of early detection device such as NUChip would significantly lower the overall cost.

Commercial Opportunity We will initially market our products for free or at a very cheap price to our target customers, namely: hospi-tals, clinics and nursing homes. Once our product is widely accepted and recognized in the market, we would increase the price and sell it to distributors.

Competitive AdvantagesCurrently, there are various technologies available in the market aiming at early detection of cancers. Howev-er, the existing products can either measure one type of biomarker at a time and/or are not sensitive enough for early detection. The ones that are capable of detecting multiple biomarkers in a single measurement are expensive and time consuming. NUChip has comparably lower cost and higher sensitivity than competitors’ products in the market. Besides these advantages, our biosensor is also capable of detecting multiple bio-markers in a relatively short time.

Future Financial Plans Funding: Requested funding amount for a 1-year (short-term) plan is $150,000.

Milestones:

1. Fabricate and assemble NUChip devices – cost of fabrication materials, cost to use manufacturing facility, and labor ($90,000)

2. Test NUChips with multiple biomarkers simultaneously in one biosensor – cost of antibodies, anti-gens, kits and reagents ($50,000)

3. Conduct experiments to study sensitivity and specificity of our measurements – (cost is covered in milestone 2)

4. Attend conferences, and technology booths to build a network and contact with Angel Investors and Venture Capitalists – cost of fees and travel ($10,000)

In the long-term, funds will be used for in-vitro and in-vivo testing in animal models and clinical samples. Below are show the deliverables and milestones from company formation to product launch.



Photoral, Inc.Presented byStamatis N. Astra, President & CEO

Company Overview PhotOral is the first in the oral care arena to commercialize an intraoral blue light technology that is scientifically proven to kill harmful bacteria, control plaque, and possibly control and cure diseases such as gin-givitis and periodontitis. The company’s two scientific founders from The Forsyth Institute are Drs. Nikos Soukos, the founder of Forsyth’s Applied Molecular Photomedicine Laboratory and Max Goodson, lead-er of Forsyth’s Translational Research Group. Stamatis N. Astra, the company’s President and CEO, is an entrepreneur who has extensive experience with

Product/Technology ProfilePhotOral, Inc. exclusively licensed from the Forsyth Institute its patented oral light technology US802114B2, granted by the U.S. Patent Office on September 20, 2011. The core of the patent is “an intraoral device that emits focused light.” The patent covers many therapeutic claims, including a wide range of use of blue light and power density that will restore the mouth to a homeostatic state by killing harmful bacteria.

Market and ApplicationThe market is an estimated $7B and includes both the therapeutic claims for the prevention and treatment of gingivitis and the control of periodontitis. The OTC aspect of the technology is a $1.7B opportunity that can reach the consumer marketplace within 12 months.

Commercial Opportunity The market is an estimated $7B and includes both the therapeutic claims for the prevention and treatment of gingivitis and the control of periodontitis. The OTC aspect of the technology is a $1.7B opportunity that can reach the consumer marketplace within 12 months.

Officers and Directors:Stamatis N. Astra, President & CEOSpiro Jamas Rhonda Bracey Tom C. PagonisAmy Gallant Sullivan

Contact Information:Stamatis N. Astra, 80 Hayden AvenueLexington, MA 02421Phone: [email protected]



Competitive AdvantagesPhotOral would be the first to be backed by clinical scientific results and to target the connection between oral and systemic health (mouth-to-body-connection), by bringing to market products that are clinically prov-en to prevent, control, and possibly cure a significant number of diseases through the delivery of blue light that targets key pathogens and stimulates the body’s innate response.

The Forsyth Institute’s reputation as a center of innovation and research will align with and educate dental professionals who will in turn become advocates of PhotOral’s patented oral light technology.

Future Financial PlansIn the process of a $800k convertible debt seed round at the moment. The funds will be used to create the working product, and conduct clinical tests.



SegterraPresented by:Gil Blander, President, Founder, and CSO

Company Overview Inside Tracker, brings a one-of-a-kind, science-based platform that helps individuals achieve optimal health and performance by measur-ing and improving their unique levels of select biomarkers. Through this personalized approach that uses a multi-factorial algorithm to cre-ate individualized ranges for healthy markers, Inside Tracker creates tailored diet, supplement and exercise plans, that not only prevent inju-ries, but optimize well-being and athletic performance.

Inside tracker demonstrates how an individual’s natural biochemistry correlates with performance and shows how nutrition and supplements can effectively manage ones biochemistry to optimize performance and athletic potential, effectively giving athletes their ‘special some-thing inside.’

Leading physicians, scientists, exercise physiologists, and nutritionists from MIT, Harvard, and Tufts University worked together to develop In-side Tracker. Inside Tracker analyzes an individual’s blood biochemis-try and provides recommendations that are based on leading scientific evidence.

Our tailored personalized recommendation is based on a dataset of more than 100,000 healthy subjects with different athletic abilities, and thousands of peer-reviewed clinical trials published in scientific journals about the relationship between biomarkers, athletic activity and lifestyle interventions such as diet, supplementation, and physical activity.

Product/Technology ProfileInsideTracker is a web-based, personalized PATH TO HEALTH, WELLNESS AND PERFORMANCE. Inside-Tracker is the only SCIENCE-BASED plan that analyzes a sample of blood and, in conjunction with your INDIVIDUAL goals FOR HEALTH OR ATHLETIC ACHIEVEMENT, provides a diet, nutrition, AND exercise plan, which is best for your SIGNATURE BIOCHEMISTRY.

InsideTracker provides superior value to its customers by combining highly relevant diagnostic biomarker panels with LOCALLY AVAILABLE FOOD, exercise AND SUPPLEMENT recommendations. InsideTracker includes the following components:

Measurement of ten key blood biomarkers;• Analysis using SegTerra’s proprietary algorithms based on scientific, peer-reviewed, clinical trial pub-• lications.


Amateur Athletes: §10.5 million customers; $0.9B total market size• Fit Consumers: §50 million customers; $2.9B total market size• Committed Dieters: 36 million customers, $1.3B total market size •

Officers and Directors:Gil Blander, CEO, FounderDavid Lester, FounderChristian Reich, Founder, VP Health IT

Contact Information:425 Woburn St., Unit 42Lexington, MA 02420Phone: 781-526-0938Fax: [email protected]://www.segterra.com



Commercial Opportunity Brand Development

Digital marketing

Endorsements

Print Advertisements

Partnering

Competitive Advantages




SIband, LLC

Presented by:George Kenney, President

Company overviewVision:

SIband has developed an innovative device and method for the on-demand release and removal of pressure sensitive adhesive (psa) ban-dages and tapes. Introduced by J&J in the 1920’s, bandaids/bandages are a $20B business providing wound protection and a barrier to infec-tion. However, we are all familiar with the pain and wound disruption of removing a psa bandage.

Core Technology and Planned Products:

SIband’s goal is to develop its device and next generation bandages for advanced wound care, gentle pediatric and geriatric adhesives, os-tomy, and other applications where bandage removal is currently a challenge in terms of either patient discomfort, wound disruption or both. An independent testing laboratory has confirmed that SIband’s device can reduce the peel force of 3M’s Transpore medical tape by 80% in a standard 900 peel test, Figure 1. SIband’s portable hand-held device fits easily within a physician or patient’s hand or nurse’s pocket. Commercial and industrial applications of psa are also being pursued.

Management’s Background and Areas of Expertise

George Kenney, President, ScD materials scientist and engineer and Associate Director of MIT’s Materials Processing Center for 30 years.

Christian Pfeffer, MD, Hannover Medical School (Germany) and PhD from Harvard University (Whitesides’s group), is currently at Boston Children’s Hospital.

Product/Technology ProfileSIband has developed and tested an innovative device and method for the on-demand release of psa’s for the removal of medical bandages and tapes. While effective with a broad range of existing products, it is best optimized when the bandage and device are designed with the other and a specific end use in mind. This portable handheld device requires no solvents, heat or external power.

Bandages have evolved to balance the need to secure the bandage in place against the need for eventual removal. The bandage industry has responded by weakening the tack force and the accepted practice is to “rip” the bandage off quickly to minimize the pain interval. The Holy Grail of psa bandages is on-demand re-lease of the adhesive with minimal pull force to minimize discomfort and wound disruption. SIband’s innova-tion is to allow the use of much more secure bandages which can be removed at much reduced pull force.

Officers and Directors:George Kenney, PresidentChristian Pfeffer, Chief Medical Officer

Contact Information:

George Kenney, President131 Green StreetMedfield, MA, 02052Phone: [email protected]



Market and ApplicationThe addressable markets for SIband’s device and technology include:

1. Medical bandages, tapes and devices:a. Advanced wound care: $8B market projected to double in 5 years based on the accelerating

need to treat ulcers resulting diabetes and varicose veins in our aging population.b. Ostomies: $2B global market with 2M patients where the product is worn constantly and re-

placed every 3 days, with security being the issue. c. Pediatric/ geriatric applications: 350K premature babies extremely sensitive to adhesives which

can leave permanent scars and 45M geriatrics with thin fragile skin.d. Transdermal drug delivery: $15B market where close adhesion is required to ensure proper

dosing.2. Commercial/Industrial PSA’s:

a. $26B market includes retail labels, industrial and commercial tapes, signage, etc.

Commercial Opportunity The medical bandage and tape market is very mature. We propose to approach sectors such as advanced wound care, where a broad range of products is required, in a collaborative development and licensing mode with sector leaders. In the ostomy sector with its singular product form (unchanged in 35 years), we propose to enter with an innovative product. The pediatric and geriatric markets have been ignored by current sup-pliers which motivates us to enter with our innovative brand of secure but extremely gentle bandages and tapes.

The industrial/commercial markets are extremely diversified. Our approach is to license our technology to leading psa suppliers and provide our device directly to their customers.

Competitive AdvantagesThe market must currently balance the desired holding force of the psa against the pain threshold of the patient or the structural integrity of the skin or other substrate. With SIband’s technology, the holding force of the psa can be independent of the pull force required to remove it. This is the Holy Grail for all psa ap-plications. SIband has filed IP.


SIband is currently operating with private angel funding and has established a testing laboratory.

SIband is seeking $3M in funding to launch design, development, test and commercialization of a lead os-tomy product line. This is expected to take 18 months from launch and will be done in collaboration with a contract development organization.



SignaBlok, Inc.

Presented by:Alexander B. Sigalov, President and Founder

Company OverviewOur vision:

With commitment to high quality innovation and cutting-edge technol-ogy, we make scientific discoveries to serve humankind and save and improve lives

Our mission:

Through innovative drug discovery science and advanced nanotech-nologies, we develop disruptive therapies and diagnostics for serious diseases with as yet unmet needs

Company overview

Founded in 2009, SignaBlok is developing a novel mechanism-based class of therapies – SCHOOL (ab-breviated from the name of a novel model of immune signaling, the Signaling Chain HOmoOLigomerization model) peptides, the innovative modulatory peptides that have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok’s is also developing a nanotechnology that enables targeted delivery of therapies and imaging agents.

In sepsis area, with DARPA support, SignaBlok is developing a novel therapy to protect against septic shock and promote survival during severe sepsis.

In oncology area, SignaBlok is developing a new anticancer therapy as its lead candidate to stop progression of solid tumors and improve survival of patients with non-small cell lung cancer, breast cancer, and pancre-atic cancer.

Management

Alexander Sigalov, Ph.D., President, Founder and Inventor, has extensive academic and industry experience (over 70 publications in the field). In the 90’s, he founded AMW Biomed Company in Russia. AMW developed and marketed the first diagnostic kits for heart disease and stroke in Russia and was the official supplier of human proteins to DAKO Denmark A/S. Dr. Sigalov is the sole inventor of methods and compositions cre-ated through the SCHOOL drug discovery platform. He also developed integrated nanosystems for targeted delivery of therapies and imaging agents to macrophage-rich sites of disease in vivo.

Product(s)/TechnologyInhibition of receptor signaling is often one of the most effective ways of preventing and treating disease. SignaBlok’s approach targets an inflammation amplifier, a specific receptor called TREM-1 (abbreviated from triggering receptor expressed on myeloid cells). In sepsis area, inhibition of TREM-1 is known to dramatically improve survival in septic animals. In oncology, recent clinical data suggest that inhibition of TREM-1 can dramatically improve survival in cancer patients.

Officers and Directors:Alexander B. Sigalov, President and Founder

Contact Information:SignaBlok, Inc., P.O. Box 4064Shrewsbury, MA 01545Phone: [email protected]



The commonly pursued strategy is to block receptor-ligand binding and requires expensive, large protein-based medicines with severe and often life-threatening side effects. SignaBlok’s proprietary peptide inhibi-tors that are developed using a new model of cell signaling, known as the SCHOOL model, inhibit TREM-1 in a novel, ligand-independent way (the so-called “Freedom to Bind, Not to Signal” strategy) and possess unique and beneficial properties.

Market and ApplicationSepsis area:

With failure of over 30 clinical trials, sepsis (blood poisoning) still causes more than 200,000 deaths in the United States each year and the number of sepsis patients is projected to increase by 1.5% per annum. On October 25, 2011, Eli Lilly announced a worldwide market withdrawal of Xigris, the only FDA-approved drug for severe sepsis, which failed to show a survival benefit in patients with severe sepsis and septic shock. Thus, there is a great unmet clinical need for a novel approach to sepsis.

Oncology area:

Non-small cell lung cancer affects over 222,000 Americans annually and is the leading cause of cancer death. Breast cancer (BC) remains the second leading cause of cancer death among women in the US. Cur-rent BC treatments have the high level of side effects and insufficient efficacy, particularly for patients with metastatic disease. Pancreatic cancer (PC) is the fourth leading cause of cancer death, with a 5-year survival rate of PC patients less than 4%.

Commercial Opportunity Our potential customers: large pharmaceutical companies, government organizations, medical device com-panies, therapeutic peptide companies, hospitals, clinics, and individual customers.

Sales/Marketing Strategy: Our path to multiplying our value lies with a capacity of communicating the value of our inventions and scientific know-how, and the ability to develop and bring innovative products to the market. Our strategies include in-house R&D, secure strategic alliances, partnerships, and licensing deals, as well as sell, divest, joint venture, and exit strategies.

Business Model: In our model, further development of our IP is complemented with collaboration with grant-ing agencies, disease foundations, academia and large Pharma on specific product R&D, and licensing out products.

Competitive Advantages

1. Breakthrough science behind our highly innovative approach to sepsis, cancer and other large market serious diseases with unmet clinical needs

2. Unique IP portfolio3. Novel mechanism-based therapies4. Novel nanotechnology for targeted delivery of drugs and imaging agents5. Extensive academic and industry experience with a unique capability to work effectively during tough

economic times6. High potential for collaboration with academia and government

Future Financial PlansFunding of $ 2.5 millions realizes our financial goals and gets SignaBlok to a significant milestone to ex-pand its portfolio of innovative technologies and establish animal proof of concept for Company’s lead drug candidate in lung, breast and pancreatic cancers. The net result of our business strategy is higher return on investment in a more reasonable, risk-balanced timeframe than our competitors.



Targeted Cell Therapies, LLC

Presented by:Edward I. Ginns, President and CEO

Company OverviewTargeted Cell Therapies (TCT) is an early stage Massachusetts based biopharmaceutical company with a powerful technology platform that enables oral delivery of DNA, siRNA and protein for treating a broad range of human conditions representing multiple billion dollar rev-enue streams. TCT’s technology is covered by a strong IP portfolio that is in-licensed from the University of Massachusetts, and encom-passes delivery, payload and several broad indications. TCT holds worldwide, exclusive licenses for applications in lysosomal storage diseases (LSDs), inflammatory conditions, and low density and lytic bone disorders. TCT intends to develop additional IP in-house and through specific project partnering in preferred disease markets.

Management includes:

Dr. Edward I. Ginns, MD, PhD, Founder, President and CEO • is Director Lysosomal Disorders Treatment and Research Program at UMass Medical School and Director, Molecular Diagnostics Laboratory at UMass Memorial Medical Center. He has more than 25 years experience in translational research and clinical practice, including new drug development. Formerly, Dr. Ginns was Chief, Clinical Neuroscience Branch at the National Institutes of Health. He is a neurologist, ge-neticist, physical chemist and eminent authority on Gaucher Disease and inherited disorders. Gilbert Addo, Jr., Chief, Business Development, holds a BS in Economics and Biomedical • Engineering from Yale University and MBA from Harvard Business School. His prior experience includes laboratory management, research on oral delivery of nanoparticles, Investor Relations at Xerox Corporation, and Decision Support for Commercial Operations at Cubist Pharmaceuticals and a health IT start-up. Siddarth Rathi, Chief, Business Strategy, holds a BS in Medical Science from Boston University’s • Seven Year Accelerated MD Degree Program and MBA from Harvard Business School. Siddarth has worked in investment management and consulted for hospital administrative offices on electronic medical record implementation. He has also worked at Quantalife where he developed the oncol-ogy diagnostics commercializing strategy for Quantalife’s droplet digital Polymerase Chain Reaction technology platform, prior to Quantalife’s recent acquisition by Biorad.

Product/Technology ProfileTCT’s technology circumvents the usual need for injection or infusion of large molecule therapeutics. The Company’s approach uses ingestable formulations consisting of nucleic acid nanoplexes or protein payloads encapsulated in glucan particles. The payloads can be comprised of DNA, siRNA, peptides, proteins or small molecules. Following oral administration, the glucan particles with their drug payload are taken up in the gastrointestinal tract by macrophages. As macrophages migrate to target tissues they become depots of the payload therapeutics. TCT’s initial applications of the oral delivery platform include the fields of lysosomal

Officers and Directors:Edward I. Ginns, President and CEO

Contact Information:Targeted Cell TherapiesMBI/Gateway Park60 Prescott StreetWorcester, MA 01605Phone: 508.363.0001Fax: 508.475.7138eginns@targetedcelltherapies.uswww.targetedcelltherapies.us



disorders, inflammatory conditions, low bone density disorders, metastatic bone disease and protein/peptide replacement. Candidate pipeline drugs include those for Gaucher disease, diabetes, inflammatory condi-tions (autoimmune, rheumatology, dermatology and gastrointestinal), osteoporosis, metastatic bone pain and disease, and hormone/protein supplementation. TCT’s orally delivered therapeutics are expected to be free of significant side effects and enable flexible dosing regimens.

Market and ApplicationTargeted Cell Therapies delivery technology has the potential to convert injectable/infusible drugs into in-gestibles, a market opportunity representing well over $21 billion dollars across multiple market segments. Segmented markets for TCT include lysosomal storage disorders (such as Gaucher disease and Fabry dis-ease) at nearly $2B, several bone conditions (including metastatic bone pain and lytic disease, osteoporosis) at approximately $2.8B, and a wide range of inflammatory disorders (diabetes, autoimmune, rheumatology, dermatology, gastrointestinal, and potentially others including CNS disorders) estimated to be over $18B ac-cording to validated external data sources.

Commercial Opportunity TCT’s immediate focus is to improve delivery of existing multi-billion dollar therapeutics, thereby positioning us to quickly bring enhanced therapeutics to market. TCT is initially directing its core technology to pursue therapies in the fields of lysosomal disorders, inflammatory diseases, low bone density conditions, metastatic bone disease and protein/peptide replacement therapeutics. TCT intends to develop additional IP in-house and through project partnering in specific disease markets. By combining macrophage targeting with pay-load versatility, our technology platform enables the delivery of a broad array of therapeutics, including DNA, siRNA, microRNA and proteins that are currently requiring administration by injection or infusion. We are leveraging our core delivery technology in several market sectors and anticipate partnering with large phar-maceutical companies aligned in specific target diseases to bring products to market. Other disease sectors and applications for this technology are also being investigated and remain viable future options.

Competitive AdvantagesOur technology platform represents a fundamental paradigm shift in the delivery of large molecule therapeu-tics and has several strategic advantages. First, local expression at diseased tissue, where macrophages are attracted, would limit undesirable, off-target systemic expression. Second, and as a consequence of more directed delivery, off-target adverse events would be reduced. This more efficient delivery will re-quire substantially less therapeutic payload and, therefore, achieve another competitive market advantage of lower drug manufacturing cost. By combining macrophage targeting with payload versatility, our technology platform is a very powerful tool for the delivery of therapeutics across a broad range of disorders. We are currently leveraging our core delivery technology in three market sectors and anticipate partnering with large pharmaceutical companies to commercialize our products. Applications for this technology in other disease sectors are also in the planning stages.

Future Financial Plans TCT anticipates a total funding need of approximately $1.5M to enter phase I (or possibly phase I/2) clinical trials for an initial product. The company’s total funding need to get through phase I trials is approximately $6M, and includes pre-clinical studies, phase I trials, the costs of developing the formulations, and additional SG&A and licensing fees. Provided TCT has sufficient resources, the company is well positioned to move quickly with a partner to bring therapies through the pipeline and into the market. If successful in negotiating a partnership in 1H 2012, the company would be able to enter phase I trials for an initial formulation before the end of 2014. The company is targeting Gaucher disease as the initial application and believes develop-ing an effective in-vivo formulation through partnership and entering phase I/2 trials to be its two immediate value creation milestones. Royalty payments to the University of Massachusetts are contingent on a number of commercial milestones as well.



TransCytos, LLC.

Presented by:Otto Prohaska, CEO and Co-Founder

Company OverviewTransCytos, LLC. has developed a novel gene transfection device (in-strument plus consumables), based on a core patent-pending, hydro-dynamic transfection technology, which it plans to market to the life sciences, biomedical, biotechnology and pharma communities. Our advantages are: efficient, fast, and highly effective transfection of cells that so far have been difficult or impossible to transfect, without the competitors’ use of special chemical compounds, electric fields, accel-erated particles, viruses, or mechanical injection. Our first product is a single transfection unit, to be followed by medium and high throughput units. Otto Prohaska, Ph.D., MBA, has, in his positions in academia, start-ups, SME and large corporations, moved from “inventor” to “com-pany-internal investor” and developed unique invention-commercialization, senior management, and lead-ership skills to raise enterprise values and returns on investments. He is working closely together with (a) the inventor, Thomas Diefenbach, with (b) Edward Kislauskis, Ph.D., a molecular genetics expert who will assume the position of VP R&D, with (c) Mark Tepper, Ph.D., a serial entrepreneur, TransCytos’ Scientific and Business Advisor, with (d) engineering experts and corporate partners for development and fabrication of our products, and with (e) application partners. Marketing and sales positions will be added as required to achieve growth expectations.

Product/Technology ProfileCurrent transfection techniques represent a considerable bottleneck for biomedical and pharmaceutical R&D due to low efficiency, high variability, cellular toxicity, and the inability to introduce genetic material into many of the most important cell types, relevant to major diseases. The majority of cells are hard or impossible to transfect with existing technologies, requiring lengthy, expensive procedures with low yield and poor repro-ducibility.

Field testing of our initial prototype instrument showed (a) transfection of previously non-transfectable cells (e.g. neurons) and (b) better transfection efficiencies and expression of gene products in a shorter period of time at lower cost (Unique Selling Propositions (USP)).

Market and ApplicationThe first generation TransCytos product, Cytofector R1, is a semi-automatic instrument for use in biomedical and pharmaceutical research labs. Frost and Sullivan estimated in 2010 that about 200 million transfections per year are conducted using existing transfection technology. The market for transfection consumables is estimated to be ~$350M. Transfections of just five cells lines make up ~50% of the total market. ~1.7 mil-lion electroporation-based transfections were performed in 2010 on higher value cell lines, costing ~$10 per transfection, with a growth forecast of more than 10% CAGR. TransCytos’ new, enabling technology is expected to expand the market.

Officers and Directors:

Otto Prohaska, CEO, Co-Founder

Contact Information:56 Maggie LaneSouthbridge, MA 01550Phone:[email protected]



Commercial Opportunity

TransCytos’ first objective is to generate an early revenue stream through the introduction of a bench-• top instrument for research use – no FDA approval is required – using a compact, growth-adjusted, direct sales force, focusing on close customer interaction in the Northeast corridor (Boston – NY – Washington).Second, TransCytos will focus on broadening the applications of its transfection processes, instru-• ments, and consumables to increase its research market share, working with a sales partner with worldwide presence. Third, TransCytos will develop a next generation medium/high-throughput transfection instrument • which will expand the market to pharmaceutical and biotech labs interested in larger scale studies on gene function and drug screening. This product development will be funded through re-investment of profits, partnerships, and Small Business Innovation Research (SBIR) grants.Fourth, TransCytos will develop its technology for use in human gene therapy with clinical applica-• tions. This phase is planned to be funded by pharmaceutical companies interested in using their drug products with our technology to facilitate advanced therapies.

Competitive AdvantagesToday, approximately 30 vendors serve the transfection market. Lipid reagents represent the largest portion of the market with about $200M in sales per year. Viral, biolistic, and microinjection techniques account for only 4% of all transfections and, combined, represent just ~$15M per year. Electroporation represents the fastest growing market share at 37% of the current transfection market and $130M in annual sales.

The TransCytos’ technology, with its USPs, is well positioned to capture a significant portion of the current transfection market worldwide; with the ability to transfect a wider range of cells, it should be able to expand the entire market which is being held back by current technological limitations.

Future Financial Plans Our current financing strategy is to raise $500,000 exclusively for the TransCytos first generation product, Cytofector R1plus consumables, to optimize product design and process performance, to manufacture the devices, and to penetrate the biomedical research market. With the investment received thus far the com-pany has built and improved a functional prototype, validated it at customer labs, and demonstrated the superior performance of the transfection technology on neurons, HUVACs, and other difficult to transfect cells. Because of our close interaction with potential customers and our work with product development partners and instrument and consumables manufacturers, and based on the sales of Cytofector R1 instru-ments and consumables to the research market, we expect to start selling the first instruments within twelve months, reaching the break-even point in the second half of year two of sales, and become self-sustainable in year three. The Cytofector R1 base product will be a “single transfection per process” instrument for basic research, capable of carrying out over 250 transfections per day. With an estimate of about 15% competi-tor market penetration by 2016 and a sales assumption of 2000 consumables per instrument per year we expect to achieve revenues of about $28 million in year 5 of sales. Additional capital may be sought around the beginning of year three of sales to support the development of the 2nd generation TransCytos transfec-tion technology products, the medium and high throughput instruments, Cytofector MTP and HTP, for large scale research and pharma. The addition of these instruments for industrial applications, as well as possible applications in gene therapy, will add substantially to the displayed bottom line.



Viridis BioPresented by:Leo E. Otterbein, Founder

Company Overview

Viridis Bio is a private, Boston-based early stage company established in 2012 and focused on harnessing the power of innate protective genes. Viridis is developing the use of biliverdin as a product of a protective gene. Our focus is to treat acute inflammatory diseases; with the ultimate economic goal being to reduce patient hospital stay by enhancing recovery from acute care centers. We are targeting kidney transplantation, which is an orphan indication and for which preclinical models have been validated. We view BV as disruptive technology that will significantly impact the standard of care from a humanitarian and economic perspective.

Team:

George Hillman has extensive experience across a broad range of strategic and operational disciplines. His background spans all aspects of company growth – from concept to financing, corporate development, technology licensing and M&A. Mr. Hillman has obtained >$150 million in starting >3 companies that have been sold or partnered. Two of his companies are now in advanced clinical trials.

Ania K. Knap, PhD is a life-sciences entrepreneur and executive with extensive experience in pharmaceutical research and early development. She is a Partner and co-founder of New England PharmAssociates LLC, a management services provider and consultancy. In 2004, she co-founded MaxThera Inc, a pharmaceutical company developing new drugs to treat life-threatening infections, where she served as President and Chief Scientific Officer. Dr. Knap has obtained >$8 million.

Product/Technology ProfileViridis anticipates that BV will increase the number of successful kidney transplants and that donor organs will function sooner, survive longer, and show less chronic rejection due to ischemia reperfusion injury. We believe that BV treatment will also significantly reduce costs by increasing the pool of organs that are viable for transplant, reducing hospital stays and by reducing dosing requirements for anti-rejection treatments.

Officers and Directors:Leo E. Otterbein, FounderGeorge Hillman, CEOAnia Knap, VP R&DKimberly Clark, VP OrganizationRob Rives, Counsel

Contact Information:Leo E. Otterbein, Associate ProfessorBeth Israel Deaconess Medical Center3 Blackfan Circle, EC/CLS 603Boston, MA 02215 Phone: 617-735-2851Fax: [email protected]



Market and ApplicationKidney transplants account for approximately 60% of all organ transplant procedures; with >25,000 trans-plants performed in the US in 2011. Approximately 70,000 people are currently on the waiting list for a kidney. With the demand far outweighing the supply, we believe BV may help expand the donor pool by rescuing organs that would normally be discarded. The average hospital stay is 5-7 days, primarily due to the time required to remove patients from dialysis because of delayed graft function. The average hospital stay is 5-7 days, primarily due to the time required to remove patients from dialysis. Patient and graft survival rates are 90% for the first year, and 80-90% post 5 years. Data from The United Network for Organ Sharing has reported that the cost per kidney transplant patient was $262,900 in 2011. The total cost for all US organ transplants exceeds $6.6B; a figure that includes procurement, physician charges, evaluation, follow-up, sur-gery costs, hospital charges, and immunosuppressant drugs for pre-surgical induction and initial therapies.

Commercial Opportunity Targeted customers would be transplant centers and recipients scheduled to receive an organ transplant. We also plan to treat donors to prevent ischemic damage and allow longer preservation storage times. Currently, the maximum storage time for a kidney is 72hrs. BV will be marketed to transplant surgeons as an alternative or supplement to current standard of care.

Competitive AdvantagesWe offer an alternative to immunosuppressives and the potential ability to reduce current immunosuppres-sive. We expect to increase the donor pool by increasing the use of marginal organs. Marginal organs have a higher incidence of delayed graft function due to increased ischemia reperfusion injury (IRI). IRI is believed to underlie the development of chronic rejection for which there is no treatment. Biliverdin has been shown to reduce IRI and prevent chronic rejection.

Future Financial PlansViridis seeks $3M for completion of preclinical proof of concept studies in large and small animal models of kidney ischemic and reperfusion injury, and in transplant models. Preclinical IND enabling studies will be completed that will allow for an IND submission. It is the intention of the company to raise additional funding or partner for Phase I or Phase I/II.



Visus TechnologyPresented by:John Wyatt, Founder

Company Overview Visus Technology is developing two products for the blind, an implant-able device and an assistive device. The first product, a pair of smart glasses, will assist a blind or visually-impaired patient with object and face identification and navigation. The second product, a retinal pros-thesis, will restore useful functional vision to patients with retinitis pig-mentosa (RP) and age-related macular degeneration (AMD), a com-bined market of many millions worldwide. Our project is a 20-year collaboration between MIT and the Massachusetts Eye and Ear Infir-mary, as well as Cornell University, the VA, Carnegie Mellon University, the University of Louisville, and the University of Alabama. Our core competencies include nanofabrication, thin film coatings, microelec-tronic circuit design, stimulating electrode chemistry, retinal surgery, and neurophysiology.

Co-founder Joseph Rizzo, MD, is the Director of Neuro-ophthalmology at MEEI, and a Professor at Harvard Medical School. He directs the project, with particular focus on the surgical and neurophysiology as-pects. Co-founder John Wyatt, PhD, is a Professor of Electrical Engi-neering at MIT, and directs the engineering effort to develop a chroni-cally implantable prosthesis. Doug Shire, PhD and Shawn Kelly, PhD oversee the microfabrication and circuit design aspects, respectively, of the product development. The company is seeking series A venture funding.

Product/Technology ProfileOur smart glasses process camera images to identify objects and text, and cue patients about their environ-ment through auditory and vibrotactile feedback. Our retinal prosthesis replaces the function of lost pho-toreceptors by electrically stimulating retinal ganglion cells in a pattern based on images from an external camera. The implanted device sits on the outside of the eye, with a thin-film electrode array that passes through the back of the eye. Patients will use the resulting pixellated vision to navigate, recognize objects, and recognize faces.

Market and ApplicationRP and AMD affect over 2 million people in America, and many more worldwide. Some estimates place the number of Americans affected by AMD as high as 10 million, and this number is expected to increase 50% by 2020. The market for the smart glasses is significantly larger, potentially as high as 25 million patients in the US. This represents a substantial market for Visus products. The total global market opportunity for smart glasses and visual prostheses could exceed $100 billion in revenues.

Officers and Directors:John Wyatt, FounderStephen McCormack, CEO

Contact Information:Stephen McCormack, CEOPhone: [email protected]



Commercial Opportunity The initial target customers for the smart glasses will be the blind and severely visually impaired. We will market to these patients via optometrists and vision clinics. The initial target customers for the implant are advanced-stage RP and AMD patients. We will market to implant patients via ophthalmologists who see RP and AMD patients, both during clinical trials and after market approval. Where appropriate, these doctors will refer patients for consultation to appropriate surgical centers.

Competitive AdvantagesOur smart glasses have no significant competitor on the market at present. A large number of groups are working to develop assistive image processing devices, but none promises to deliver the comprehensive system that we are developing, and none is aimed at helping the visually impaired. Our technology and IP represent a competitive advantage.

Likewise, other visual prosthesis groups are trying to enter the market. Some stimulate visual portions of the brain, but they miss the more accurate visual mapping at the retina. Others place electrodes on the eye’s epiretinal surface, held by tacks or glue, increasing the potential for retinal damage. Our animal experiments show the advantages of our minimally-invasive subretinal approach, where the bulk of the implant sits out-side the eye and the electrode array is held by the retina. Our group has patent protection for this design, representing a significant advantage.

Future Financial PlansWe have raised $35M in non-dilutive grant funding over the last two decades. Visus requires two years to bring our smart glasses to market, and six years to bring our implant to market through clinical trials. The total development cost will be $13M for the smart glasses and $30M for the implant, most of which will be supported by smart glasses sales. The required outside funding will be $29M.

We seek a series A of $8M to produce the glasses and the prosthesis. This funding will cover salaries, capital expenditures, vendors, and FDA regulatory and infrastructure expenses. We will seek a second round or a development partner when these milestones are reached. The second round of $11M will launch the smart glasses and fund Phase I prosthesis trials, and a third round of $10M will scale smart glasses marketing and complete implant clinical trials.



VitaThreadsPresented by:Glenn Gaudette, Founder

Company Overview Regeneration of damaged/diseased tissue is a significant unmet clini-cal need. For example, cardiac muscle damaged by myocardial infarc-tion cannot be completely restored, resulting in a weakened heart and shortened life expectancy. For this and similar diseases, cell therapy has been proposed. However, as recently stated in Nature Reports, “If stem cell therapies are going to succeed in the clinic, researchers must determine the safest and most efficient ways to transplant cells into the body.”

VitaThreads are a fibrin microthread product for delivery of stem or progenitor cells to damaged or diseased tissue. VitaThreads can be delivered as sutures to the area of interest or inserted into an inci-sion or wound site. VitaThreads have applications wherever tissue regeneration or cell therapy is required. To date, delivery to heart, muscle and wounds have been successfully demonstrated. Near term opportunities exist for a product sold to the research community and to the veterinary market. High-value human applications include cardiac, skeletal muscle and soft tissue regeneration.

VitaThreads is a pre-seed company in formation with technology from Worcester Polytechnic Institute. Vi-taThreads has assembled a team of scientific inventors, academic advisors, industry consultants and sub-ject-matter experts to develop and commercialize this technology.

Product/Technology ProfileThe delivery of therapeutic cells to injured or diseased tissues is a promising method for facilitating the re-generation of new tissue for many different organ systems. For example, human mesenchymal stem cells (hMSCs) have been utilized to improve cardiac function by increasing vascularity as well as limiting scarring in the infarction zone. However, current cell delivery approaches, including intravenous delivery and direct injection, are inefficient due to low cell retention and a lack of targeted localization. We developed novel bio-polymer sutures (VitaSutures), made from biodegradable fibrin, to facilitate targeted localization of stem cells using a needle-guided delivery technique. These VitaSutures deliver hMSCs to the heart with greater than 65% efficiency, significantly greater than intramyocardial injection (12%). These results illustrate that VitaSu-tures can serve as an efficient means of delivering stem cells to tissue. Unlike the currently utilized delivery methods, VitaSutures can target areas for cell delivery and maximize cell engraftment, thereby reducing cell numbers needed for delivery.


Officers and Directors:Glenn Gaudette, FounderGeorge Pins, Founder

Contact Information:Glenn GaudetteAssociate ProfessorBiomedical EngineeringWPI100 Institute RoadWorcester, MA 01609Phone: 508-831-6086Fax: [email protected]



Within one year of initial funding, we plan to initially offer VitaSutures to the research market (Market size ~ $50,000/year) and the veterinarian market (Market size ~ $5M/year). We will simultaneously develop these sutures for human clinical applications. The market for delivery of mesenchymal stem cells in the heart is extremely attractive. According to the American Heart Association (AHA) 8.1 million Americans experienced acute myocardial infarctions and 5.3 million Americans had heart failure in 2005. We believe an initial product based on our absorbable suture technology will be used in surgical procedures, while future products will be endovascular based and will be delivered through standard catheter techniques. More than half a million heart surgeries are performed each year in America alone, and approximately ten percent of the total number of coronary interventional procedures (stent and angioplasty) are performed on acute myocardial infarction (AMI) patients.

Commercial Opportunity We are currently exploring opportunities with KeraFast to sell VitaSutures to the research market. In re-gards to the veterinarian market, we are working with Harry Wotton, who started, grew and sold Securos, which distributes veterinarian products throughout the US and Europe. We plan to continue to develop Vi-taSutures for clinical applications and currently envision myocardial infarctions as our first clinical target.

Competitive AdvantagesDelivery of cells to the heart has been shown to be beneficial to infarcted patients. However, all current methods have low cell engraftment rates, in addition to other limitations. Intramyocardial injection requires the injection of a certain volume of cell suspension directly into a myocardial wall. However, once the sy-ringe needle is removed, the cells are pushed out due to the contraction of the heart. Systemic delivery lacks localization; when cells are delivered systemically, a majority of the cells engraft in organs other than the heart including the liver, lungs, and spleen. Given the low engraftment rates, current studies are delivering 10 to 50 times more cells than are needed, resulting in a large waste of resources used to manufacture these cells.

One company that is attempting to address the delivery issue is Biotime. They are developing a hydrogel based delivery system (Hy-Stem Rx), where cells are incorporated into the gel. However, this gel still has engraftment issues. Biosense Webster has a catheter that can be used for intramyocardial injections. We anticipate that this catheter can be converted to allow for endovascular delivery of VitaSutures.

Future Financial PlansWe are currently seeking a $500,000 investment (through equity and grants) for intellectual property li-censes, defining manufacturing processes, personnel and supplies for research laboratory sales and for proof of concept for veterinarian applications. In year 2, we plan to seek additional investment of $5M for personnel and supplies for veterinarian sales, proof of concept for human applications, and IND filing.

52 Exhibitors


Exhibitors 53


Additional Exhibitor ProfilesAdvirna ....................................................................................................................................... 54

Alexey Wolfson, Founder

Binotech Laboratories, Inc. .................................................................................................. 56Andrew N. Makarovskiy, Founder, President and CSO

ColdSteel Laser ........................................................................................................................ 58Frank Palmer, CEO

Excellims Corporation ........................................................................................................... 60Ching Wu, President

Massachusetts General Hospital ........................................................................................ 62Jerome L. Ackerman, Associate Professor of Radiology

Nanocanary Technologies................................................................................................... 64Susan Braunhut, Professor

Spordiff Therapeutics, Inc. .................................................................................................... 66John Cosmopoulos, Senior Associate Director for Licensing

Synthegenix Pharmaceuticals ............................................................................................. 67Mark Grier, CSO and Founder

University of Massachusetts Medical School .................................................................. 68Paul D. Kaufman, Professor

ZS Genetics, Inc. ...................................................................................................................... 69Thomas Abert, Vice President

54 Exhibitors


AdvirnaPresented by:Alexey Wolfson, Founder

Company Overview

Advirna is a biotechnology start-up focusing on commercialization of a next generation of RNAi reagents. RNAi is a Nobel prize winning technology to selectively manipulate genes activity in living cell for research and clinical applications. The major limitation of current RNAi technology is lack of efficient and non toxic delivery. RNAi reagent (short double-stranded RNA) requires a lipid formulation to penetrate cells. This method is applicable to a limited number of cell types, which significantly restricts research and clinical applications. In collaboration with RXi Pharmaceutical Advirna has developed a next generation of RNAi reagents- self delivering RNAs(sdRNA). sdRNAs do not require formulation for efficient cellular uptake and work in all cell types and in vivo. sd-RNAi is disruptive technology significantly expanding the utility of RNAi in research and clinic and substantially increasing the addressable market. Advirna obtained from RXi Pharmaceuticals an exclusive license for sd-RNAi technology in research tool business and functional genomics. Advirna’s goal is make sd-RNAi technology available to a broad scientific community. Advirna’s founders and advisors are experts in nucleic acid technologies and have been key players in the creation of three successful RNAicompanies (Dharmacon, part of ThermoFisher, Sequitur, part of Life Technoloiges, and Rxi Pharmaceuticals.

Product/Technology ProfileAdvirna is a biotech research tool business company providing the technological solutions and reagents for the specific knockdown of gene activity in animal and human cells using RNA interference. The RNAi technology is widely used in Life Science research and has a broad customer base including academia and industry. The major limitation of the current RNAi technologies is inability to efficiently knockdown genes in primary and stem cells as well as in vivo and in ex-vivo systems. In recent years it became clear that study-ing functions of genes in their natural environment (i.e in the primary cells or inside the organism) is crucial for understanding of their functions and for successful target validation and drug development. Advirna has developed a proprietary RNAi technology which significantly expands the limits of the currently used tech-niques into these application areas. Advirna’s self-deliverable RNAi technology is a simple tool to regulate gene expression in the most important cells lines (stem cells, primary cell lines) as well as in vivo and ex-vivo. Advirna’s technology effectively enables the entrance of researchers into the new area of in vivo functional genomics. On top of that self-deliverable RNAi is a disruptive technology capable to substitute currently ex-isting technologies in almost all current applications.

The currently addressable market for RNAi technologies is estimated at $250-300 millions and is expanding with 15% CAGR. In addition to existing market, Advirna’s self-deliverable RNAi technology enables efficient delivery to all cell types, including primary cells and in vivo target validation. These two additionally market

Officers and Directors: Alexey Wolfson, FounderAnastasia Khvorova, Founder

Contact Information:10 Rocklawn rdWestborough MA 01581Boston MA 2215Phone: 720- 936 [email protected]

Exhibitors 55


segments are essentially not addressed and represent Advirna’s immediate market opportunity. Recent mar-ket reviews indicated that ability to deliver RNAI to primary cells and efficacy in ex-vivo and in vivo applica-tions are the two major desired RNAI product features, where customer satisfaction is low. These two niche markets size are estimated to be between 10-80M$ and expected to grow fast with availability of appropriate research tools. These niche markets represent a great entry opportunity due to unmet demand, low competi-tion, and significant population of highly enthusiastic not- price sensitive customers (“Early adapters type”). Initial penetration through this niche market will be followed by expansion into traditional RNAi market.

The aim of Advirna is to bring eventually the self-deliverable RNAi technology to every research bench. To penetrate the market Advirna will work with opinion leaders in industry and academia to create a group of influential early adopters, produce peer-reviewed publications and gain name recognition. Initial Advirna’s customers are big academic labs and biotech companies working with biological systems where self-deliv-erable RNAi technology provides an efficient solution (i.e in vivo target validation and functional genomics is primary cells and ex-vivo systems). With developing of technology, gaining name recognition and sales volume Advirna will expand to a broad research market

Future Financial PlansAdvirna is seeking seed/round A financing to start operations and penetrate the market at the amount up to $3M in two years. The funds will be used to develop operations (outsourcing model), marketing, partial subsi-dizing the cost of reagents for early adopters and creating a catalog of reagents. As of today Advirna received $230K in SBIR funding and has over $1M in committed SBIR funding. Advirna is expected to deliver the first products in 2011 and achieve sales of $100.000 and $1M in the first and second years of operations and transition to profitability in the third year. The exit strategy is an acquisition by a major research tool business company on the fourth or fifth year of operations.

56 Exhibitors


Binotech Laboratories, Inc.Presented by:Andrew N. Makarovskiy, Founder, President and CSO

Company OverviewBinotech Laboratories, Inc. (“Binotech”) is a start-up biotechnology company focused on developing novel immuno-therapeutics and vac-cines targeting tumor stem cells.

Core Technology

Binotech’s Core Technology is based on the proprietary method to de-velop monoclonal antibodies specific to the cell surface markers ex-pressed by the stem cells in tumors. This unique platform technology proved successful in producing new markers to both normal and tumor prostate stem cells and can be applied similarly to other human tissues. Currently available antibodies are the cornerstone for the development of curative treatments for tumors. Thus far selected new antibodies were not growth inhibitory on their own and therefore will be developed as delivery vehicles for toxins (immuno-conjugates) or ADC (antibody-drug conjugates). The new antibodies will be also used to identify corresponding stem cell specific surface anti-gens. Peptides derived from these antigens will serve as a polyvalent vaccine to treat cancer. Binotech’s first panel of stem cell specific antibodies was developed to treat benign prostate hyperplasia (BPH) and malig-nant prostate tumors (Cancer).

Management

Dr. Andrew N. Makarovskiy, M.D. founded the Company (Delaware Corp.) to pursue commercial develop-ment of his discoveries made at Brown University. He is holding the position of President and Chief Scientist at Binotech and is responsible for the initial stages of corporate development. At present, Dr. Makarovskiy holds an appointment of a Research Assistant Professor at the Department of Urology Tufts University/Tufts Medical Center.

Product/Technology ProfileTwo lines of products will be developed: “BinoFLOW” – an antibody-toxin based treatment for Benign Pros-tate Hyperplasia and “BinoVAC” – Cancer specific immunotherapy.

BinoFLOW: The Company will develop a new treatment modality for Benign Prostate Hyperplasia. A stem cell specific monoclonal antibody will be genetically modified to become a construct composed of an anti-body fragment and potent plant toxin. This construct will allow targeting of stem cells in benign prostate tu-mors. Elimination of the stem cells from the benign prostate tumors will result in shrinkage of the tumor and alleviation of symptoms associated with it. The treatment will be administered by direct injection into enlarged prostate to achieve maximum efficacy. Treatment is irreversible and will prevent recurrence of the tumor after one or two administrations of the antibody-toxin.

BinoVAC: The Company’s second product is a novel therapeutic approach to cancerous tumors. The treat-ment will be systemic to allow eradication of both primary and secondary prostate tumors that have spread in advanced stages of the disease. Immune system will be exposed to a mixture of the synthetic peptides (fractions of proteins) that stem cell specific antibodies recognize. This will facilitate a specific killing activity of immune system against tumor stem cells, e.g. therapeutic cancer vaccine.

Officers and Directors: Andrew Makarovskiy, Founder, President and CSO

Contact Information:32 Vincent Rd. Mendon, MA 01756Phone: 617- 636-6382 [email protected]

Exhibitors 57


Immunotherapeutics will be developed based on the already available monoclonal antibodies. In parallel, proprietary core technologies to produce and characterize additional stem cell (SC) specific markers will be also utilized. This “double dipping” strategy will allow incorporation of the new knowledge, markers and anti-bodies in the follow-up optimization to achieve the most favorable therapeutic results.

Market and ApplicationProstate growth related pathologies (BPH and Cancer) are a major and increasing public concern due to aging population. In US alone prostate treatments represent a $5.5 BB/year opportunity (combined for BPH and cancer).

Commercial OpportunitiesThe Company intends to fully develop its products and bring them to the market in collaboration with a sea-soned pharmaceutical partner. Monoclonal antibodies specific to antigens on human stem cells are a product of its own and can be out-licensed or co-developed in partnership with other biotechnology companies.

Competitive AdvantagesThe Company holds fundamental patent (# 6,632,620) that covers the most important antibodies enabling identification and isolation of the adult and fetal stem cells in various organs and tissues including prostate. An additional patent # 7223549 (CIP) further solidifies the Company’s IP position in the field and protects the Company’s approaches to developing new immunotherapeutics. The most important antibodies were also deposited (PTA 4655) to American Type Culture Collection (ATCC). Other research approaches and cell lines are major proprietary assets of Binotech. New patents covering therapeutic applications and companion di-agnostics based on the Company’s core technology are planned to further strengthen IP position.

There is a great deal of competition in the tumor stem cell research field and Binotech’s unique technolo-gies and scientific findings remain proprietary to enable “first to the market” approach. FDA approval and introduction to the market of a prostate cancer vaccine Provenge last year paved the road for similar immuno therapeutics and will simplify marketing of Binotech’s products. Most recently, Binotech produced a working prototype of an immuno-toxin using our lead antibody exclusively specific to both normal and tumor stem cells of the prostate and a potent toxin derived from a plant. This conjugate was able to completely obliter-ate either normal or prostate cancer cells in vitro thus providing experimental evidence proving the concept that selective targeting of the stem cells will indeed suppress the growth of the entire cellular population maintained by these stem cells. Furthermore, this therapeutic proof of concept was also confirmed in an in vivo prostate cancer model when established tumors were successfully eradicated using the immunotoxin. Present efforts are focused on developing recombinant toxin that will allow mass production and simplify preparation of the antibody-toxin conjugates.

What differentiates Binotech from competition is the availability of an extensive panel of Binotech’s antibod-ies to stem cells that enables to distinguish normal from tumor stem cells. These antibodies also enable to select for subtypes of stem cells within a tissue - a major advantage over competition currently unaware of the existence of such stem cell subtypes and their individual role in tissue and tumor maintenance. This proprietary knowledge is a key to selecting most valuable cellular and molecular targets that will ensure com-plete tumor inhibition and prevention of tumor recurrence.

Future Financial PlansBinotech is looking to raise ~7MM in a Series A round of financing. The A round of financing should enable the Company to fully develop the prototypes of BPH treatment and cancer vaccine and prepare for IND sub-mission and clinical trials. A smaller (1.3-1.5M) seed round can be carved out towards the round A to reduce the risk of the initial investment and yet provide sufficient startup funds to establish company’s operations and deliver important milestones before closing full round A.

58 Exhibitors


ColdSteel LaserPresented by:Frank Palmer, CEO

Company OverviewColdSteel Laser (CSL) is a medical device company that is leading the development of the Endoscopic Laser Scalpel (ELS) as a platform technology to combine new advances in laser surgery with remote vi-sualization and manipulation in minimally invasive surgeries. Current technologies require direct line-of-sight access to the surgical field and have external manual operation of the laser. With our proprietary laser scalpel, we can focus the laser specifically around tissue to be ex-cised, with more precision and internal control than current technology available. We are also able to visualize tissue that has been previously impossible to reach with current laparoscopic techniques and to control excisions remotely on an external tablet. The technology will improve the efficacy of laser surgery, reduce the risk of surgical complications, and increase the number of patients that can benefit from minimally invasive laser surgery.

Product/Technology ProfileThe ELS is a remotely controlled, image guided, endoscopic surgical laser small enough to fit in confined anatomical spaces (ENT, GI, male and female reproductive systems, respiratory system). It translates a surgeon’s command from a mouse or stylus to a device the size of a small coin positioned deep inside the body. A camera inside the device provides an image of the surgical field and an optical steering mechanism nimbly allows point-and-click control of a focused laser beam.

Markets and ApplicationThe target market consists of patients undergoing surgery to physiologically enclosed anatomic sites. There were approximately 3.5 million patients with malignant and benign growths in 2011 (US, Brazil, India, Eu-rope) who would have benefited from the minimally invasive approach of the ELS.

Commercial OpportunityThe device will be sold to hospitals and surgical centers as capital equipment but will also include an annual subscription for technical support/software licensing and per procedure revenue generated from a dispos-able outer sheath designed to maintain sterilization.

Officers and Directors:

Frank Palmer, CEOSnehal PatelMilind RajadhyakshaRicardo Toledo-Crow

Contact Information:

636 Campgaw RdMahwah, NJ 07430Phone: [email protected]

Exhibitors 59


Competitive Advantage Current technologies cut tissue using an electrocautery or laser. Electrocauteries often require open surgical approaches and the heat/current can cause significant damage to surrounding tissues. The laser requires external control and direct line-of-sight to the surgical field. It can be likened to signing one’s name by hold-ing the eraser end of an 18 inch pencil. Many laser technologies also introduce a divergent beam, requiring precise placement for the laser to be an effective cutting tool. The competitive advantages of the ELS are:

Size and Position: The ELS is the size of small coin and can be guided to previously unreachable tis-• sue in GI, GU, laryngeal and abdominal spaces.. Due to its size and the tissue it can reach, the ELS reduces the need for radical and invasive surgical approaches. Minimally invasive surgery is associ-ated with fewer post-operative complications, faster healing times, and lower post-operative pain.Remote Manipulation: Since the ELS is controlled remotely, optical manipulation of the laser beam • is performed inside the body. Control of the laser closer to the surgical field is more accurate than control from a distance.Focused Beam: The ELS uses internal optics to focus the laser beam. The focused beam reduces • collateral tissue damage and improves post-operative tissue/organ functions.

These advantages are not only good for the well-being of patients undergoing surgeries, but they also pro-vide an overall reduction of a hospital’s in- and out- patient costs.

Future Financial PlansBoth hardware and software components of the ELS technology have been developed and patents for the laser scalpel are pending in the US. To further develop an advanced control system (point-and-click control of the laser), license the technology from MSKCC, protect the IP internationally, and bring the ELS into animal testing, $1 million will be required in the next year. To redesign the ELS for cost, navigate FDA regulations, and bring the ELS into the first patient, an additional $2 million will be required by the end of year two. The product is expected to be sold or sublicensed for sale between years four and six.

60 Exhibitors


Excellims CorporationPresented by:Ching Wu, President

Company OverviewFounded in 2005, Excellims Corporation researches, develops and manufactures high performance ion mobility spectrometers and ion mobility- mass spectrometers. Excellims is led by Dr. Ching Wu, Presi-dent, one of the leading IMS scientists in the world. He has 20 years of IMS and MS instrumentation research and has extensive industrial R&D experience in instrument development at Bruker and GE. Paul Eisen-braun joined Dr. Wu as a founder of the company and is Chairman. Mr. Eisenbraun was one of four members of the senior management team of Ion Track Instruments who were equity participants in the LMBO of Ion Track from Shroder Ventures (now Permira) in 1999 followed by the acquisition of Ion Track by General Electric in 2002. To date, Excellims has been funded by its founders and by successfully winning competi-tive research grants from several US government agencies totally more than $6.3M. Excellims is a focused technology company that employs highly specialized staffs (5 PhD and 3 MS) who have extensive knowledge / experience in analytical instrument development and manufacturing. Excellims has three products ready for market and is looking for funding to develop its sales, marketing and production capabilities. Excellims owns significant IP related to IMS technology.

Product/Technology ProfileExcellims’ innovative Electrospray ionization – High Performance Ion Mobility Spectrometer (ESI-HPIMS) offers separation efficacy comparable to modern UPLC systems but at higher speed and much lower op-erating cost. Excellims novel DirectSprayTM sample introduction allows direct analysis in seconds from common laboratory syringes using the syringe needle as the ESI source or an autosampler may be used. Using disposable syringes eliminates clean up procedures. DirectsprayTM analysis takes seconds at 1/100 operational cost compared to conventional HPLC. By eliminating organic solvents in the separation process, HPIMS is a green analytical technology that benefits the environment and saves operational cost. HPIMS is available as a standalone system, appended system for existing mass spectrometers (MS), and as an integrated system with MS.

Markets and ApplicationsjHPIMS can replace HPLC for many pharmaceutical analysis needs, such as chemical synthesis reaction monitoring, pharmaceutical cleaning verification, and QA/QC on incoming materials and finished products. HPIMS offers speed and cost advantages whenever large volume/high throughput screening of targeted compounds or biological samples is required.

Officers and Directors:Ching Wu, President

Paul Eisenbraun

Contact Information:Ching Wu 20 Main StreetActon, MA01720Phone: 978-264-1980 x112Fax: [email protected]

Exhibitors 61


Commercial OpportunityAlthough UPLC and SFC systems with higher separation speed and reduced solvent use have begun to replace HPLC , HPIMS offers similar separation efficacy based on an orthogonal principle and:

replaces HPLC where HPIMS provides the same separation with even higher speed and lower op-• erational cost;offers an alternative where HPLC/UPLC is not effective or requires extensive method development;• provides an orthogonal separation capability when used with HPLC and MS systems. •

The initial target market is the pharmaceutical industry since it uses 35% of all HPLC systems. We have worked closely with several major pharmaceutical companies to develop the applications we are initially tar-geting. This work has helped to define the required instrument features. We will continue to attend meetings such as Pittcon, ASMS, and ACS and with funding will start to include Interphex and other pharmaceutical specialty events. We will also use funding to build additional demonstration instruments and hire sales and applications personnel that can take the instrument to customer’s sites.

Competitive Advantage HPIMS is faster and has lower operating costs than HPLC or UPLC. Excellims owns more than 50 US and international patents and applications surrounding the HPIMS technology that enable multiple generations of products that address additional markets. Patented concepts include chiral IMS, interactive IMS where drift gas modification allows “on the fly” changes to drift gas properties, and multidimensional IMS that will enable HPIMS to effectively compete in broader areas of the chromatography marketplace.

Future Financial PlansFunding required: $3-4 Million

Use of the funding:

Fill out management team – Add CFO, VP Sales, Production Mgr• Demo instruments, sales staff, travel, trade shows, marketing materials• Additional R&D staff, production staff• Production planning, purchasing, inventory and fulfillment software and management• Capital for inventory, office equipment•

Milestones to be accomplished:

Hiring sales and applications staff –3 months• Build 4 HPIMS demonstration systems –4 months• Hire CFO and production manager – 6 months• Transition HPIMS manufacturing to a contract manufacturer -12 months• Cash positive in operations – 3 years•

62 Exhibitors


Massachusetts General HospitalPresented by:Jerome L. Ackerman, Associate Professor of Radiology

Product/Technology ProfileMagnetic Resonance Mediated Radiofrequency Ablation

(MR-RFA)

Radiofrequency ablation (RFA) is a minimally invasive means to treat tumors by the application of electrically generated heat. Typically used to kill (ablate) small well-localized tumors of the liver or breast, in RFA a needle is inserted through the skin into the tumor, a large area ground pad is affixed to the patient’s limb, and an electric current is passed between these electrodes. Electrical heating induces tissue damage intended to kill the tumor while sparing the surrounding normal tissue.

Conventional RFA has a number of problems. RFA-treated tumors have a relatively high recurrence rate because the interventionalist does not know the tissue temperature, and therefore cannot determine if the en-tire malignancy has reached the kill temperature, often erring on the conservative side by limiting heat to avoid extensive organ damage. Patients can experience severe skin burns under the ground pad or through inadvertent contact with other conductive structures if a ground fault occurs. Tumor localization and needle guidance are often accom-plished with CT scanning, which exhibits poor soft tissue contrast and requires administration of a contrast agent, with its associated risk of toxicity. RFA carried out under MRI guidance requires specially adapted RFA equipment to reduce interference between the MRI scanner and the RFA equipment, and introduces additional safety risks.

Magnetic resonance mediated radiofrequency ablation radically alters the means by which heat is ap-plied to tumors, and enables far superior control and monitoring of the procedure, while enhancing safety. The MR-RFA procedure is carried out in an MRI scanner, which functions as the source of heat energy as well as providing the superior diagnostic imaging functions of MRI. An antenna placed within the MRI scan-ner harvests electromagnetic energy from the scanner, and channels it in a controlled fashion to the tumor. The advantages of MR-RFA over conventional RFA include:

• Excellent tumor and soft tissue visualization without contrast agents• Real-time imaging during the procedure• Means to image the temperature of the tissue and tumor• Means to image blood perfusion, flow and coagulation• Elimination of the ground pad• Elimination of electrical connections to external RFA equipment• Elimination of the RFA generator• Production and control of heating by means of the MRI scanner• Potential for complete intraprocedural surgical planning, control and monitoring by means of an au-

tomatic feedback system

Officers and Directors:Jerome L. Ackerman,

Associate Professor of Radiology

Contact Information:Jerome L. AckermanMartinos Center for Biomedical ImagingMassachusetts General Hospital149 13th StreetCharlestown, MA 02129Phone: 617-726-3083Fax: [email protected]

Exhibitors 63


Together these features represent a quantum advance in the treatment of tumors by RFA. If MR-RFA can enable a larger cohort of patients to be treated by a minimally invasive procedure, and can lower tumor recurrence rates, better patient outcomes will be achieved, and overall treatment costs will be significantly lowered.

Markets and ApplicationsThe total world market for ablation of solid cancers by directed energy is expected to exceed $8.6B (“Abla-tion Technologies Worldwide Market 2008-2017,” MedMarket Diligence, Report A125, September 2008), and this value is trending higher. In 2007, conventional RFA was 9% of this total market, and 57% of the total was in the Americas. In 2011 there were about 30 million MRI procedures (CAGR 6.3%), of which 8.6% were interventional or surgical (CAGR 9.3%). Those MRI procedures involving directed energy (conventional RFA adapted to the MRI environment) were 0.26% of all MRIs, but the CAGR was 12.2%, a very rapid growth, which we believe is hindered by the issues the new MR-RFA technology is intended to address.

Commercial OpportunityThe target customers are interventionalists (initially radiologists, but later cardiologists and neurosurgeons) and their institutions. We are extending MR-RFA to develop new proprietary technology of particular interest to these additional customers and markets.

Competitive Advantage The technology description above catalogs the problems with current RFA methodology, and how the new MR-RFA technology addresses these problems. Improved patient outcomes (lower patient morbidity and re-covery times, reduced tumor recurrence rates) and lower overall costs (day surgical procedure, no overnight hospital stays) will sustain the competitive advantage, especially in light of continuing pressure from third party payers to reduce costs.

Future Financial Plans Funding of $5M over three years is sought to reach these milestones:

Develop a clinical prototype disposable MR-RFA needle system• Optimize performance using tissues and animals• Characterize safety, reliability and performance• Perform pilot clinical studies of efficacy in liver cancer patients•

64 Exhibitors


Nanocanary TechnologiesPresented by:Susan Braunhut, Professor

Product/Technology ProfileA novel cell-based acoustic wave (AW) device, which makes human cells surrogates for tissue and animals for monitoring and testing chem-icals, materials and formulations. This biosensor characterizes the me-chanical as well as the viscoelastic properties of the cells. It is capable of simultaneously driving a piezoelectric quartz crystal to oscillate at multiple frequencies and this frequency dependent response can be used to obtain unique detailed information and diagnose of the status of the cell in response to drugs, toxins, pathogens, etc. The quartz crys-tal microbalance (QCM) based biosensor has been considerably devel-oped and provides multiple proof-of-principle data. A high throughput surface acoustic wave (SAW) device is currently under development for commercialization. The portfolio of acoustic wave devices utilizing cells has been trademarked under the term “Nanocanary” technologies.

Markets and ApplicationsNanocanary is a platform technology, which has several distinct appli-cations in the area of nanomaterial and chemical toxicity testing, drug discovery, and as a basic cell biology research tool. The global market for biosensors in 2009 was valued at $6.72 billion. The nanotechnology market is a booming segment with currently more than 1,000 nano-based products on the market. The US market for biosensor rapid detection of nanoparticles was valued at $765 million in 2006. This market is ex-pected to double by 2011, forecast to have a $1.5 billion value. Global drug discovery technology market is in excess of $57 billion as reported by Global Industry Analysts, Inc. They estimate this global high throughput screening (HTS) market will reach $19.9 Billion by 2017.

Commercial OpportunitySeveral prototypes of this device can be tested in different research laboratories in life science and biomedi-cine departments in academic and biotechnology company settings for studying cell responses to agents or changes in their environment. The cell biology research tool will be the entry market for this device. Many companies worldwide

are producing large numbers of engineered nanomaterial products (> 2,400) with little if any testing for toxic-ity. The EPA is beginning to require testing and while animal studies are not possible at such large scale, no alternative functional tests exist. Providing either service or product to such companies will be our objective. Drug development applications are numerous where downstream high value added testing of drug candi-dates for human cell activity is a priority.

Officers and Directors:Ching Wu, President

Paul Eisenbraun

Contact Information:Susan BraunhutUniversity of Massachusetts-LowellOne University Ave.Lowell, MA 01854Phone: 978-934-2876Fax: [email protected]

Exhibitors 65


Competitive Advantage The Nanocanary is the ultimate biological machine and a generic device, which can be used with any ad-herent cell type and applied to any human disease, general toxicology and systems biology.

The Nanocanary platform uses mixtures of cells that when reconstituted represent tissues, organs or even animals with the potential to reduce the number of animals and organs harvested from animals for drug development or toxicology testing and biological research. This robust, low cost cell biosensor would be first to market as they have never been developed for use outside the pure research academic lab setting.

There is a critical need for novel rapid approaches to toxicity testing of engineered nanomaterials. This device is highly advantageous when time is of the essence and also from a safety standpoint. Customized therapeutic guidance, non-anatomical diagnosis, prognosis methods are needed particularly for early le-sions, that today are being discovered more commonly and earlier due to early detection methods such as digital mammogram screening and PSA testing. Drug discovery screening for a host of anti-cancer and anti-infectious agents are other applications possible using this platform technology.


Will seek:

Series A financing 2012

$1.5 – 2 million round

Establish Corporate Structure

Develop High Throughput SAW prototype Devices

Build and test 3 beta instrument platforms

Validate Market Application

Develop Commercial launch plan

Series B financing 2013

$3-4 million for Product Commercialization

66 Exhibitors


Spordiff Therapeutics, Inc.Presented by:John Cosmopoulos, Senior Associate Director for Licensing

Company OverviewSpordiff is developing small molecule inhibitors of C. diff germinant re-ceptors to prevent onset or relapse of antibiotic-associated colitis and reduce the $4 billion annual cost of this complication in the US.

Product/Technology ProfileSpordiff’s products are based on discoveries made at Tufts University regarding promoters and inhibitors of C. diff spore germination. Inhibi-tion of spore germination will prevent onset of C. diff-caused antibiotic-associated colitis (AAC), a potentially severe complication that prolongs hospitalization and can be fatal.

Markets and ApplicationsCurrently patients are treated after becoming ill with AAC by administering C. diff-specific antibiotics. Spor-diff products will be given concurrently with the antibiotic treating the patient’s primary condition, reducing or preventing the complication of AAC. Patients will avoid the morbidity of AAC (which can be devastating), and the second course of C. diff-specific antibiotics will be unnecessary as will all the associated costs of a prolonged hospital stay.

Commercial OpportunityIn the US, $4 billion is spent annually to care for AAC, a small portion of which pays for the C. diff-specific antibiotics. Spordiff products would NOT compete directly with these antibiotics, but would be administered more widely in order to inhibit onset of AAC. The true commercial competition is the choice of treating after the onset of disease; thus a market opportunity of up to $4B is possible given a better outcome.

Competitive Advantage Spordiff products will prevent onset of AAC through a specific receptor-mediated mechanism. All other prod-ucts used for AAC (or in development) treat active disease. With hospitals increasingly at risk of reduced payments for preventable complications, an effective inhibitor will be enormously attractive.

Future Financial PlansSpordiff is raising approximately $20 million in venture funding that will support a virtual development plan through a Phase 2a Proof of Concept clinical trial.

Officers and Directors:John Cosmopoulos,Senior Associate Director for LicensingFrederick Jones, CEO

Contact Information:Frederick Jones Spordiff Therapeutics, Inc.Phone: [email protected]

Exhibitors 67


Synthegenix PharmaceuticalsPresented by:Mark Grier, CSO and Founder

Company OverviewSynthegenix Pharmaceuticals founded on 10 years R&D experience in bacteria science is discovering and developing a revolutionary technol-ogy in targeted bacteriotherapy to treat cancer.

Product/Technology ProfileA cytotoxic or immunotherapy bacteria adjunct drug combination for a targeted approach to treat cancerous tumors where the technology is well suited for treatment in relapsed cancer drug resistant patient populations.

Markets and Applications$11B colorectal market is our first niche with 5% initial share.

Commercial OpportunityA commercial opportunity as a new therapy to treat aggressive resistant tumors in colon cancer.

Competitive Advantage The technology has an advantage in being immune to cancer drug resistance.

Future Financial PlansAn early seed stage funding is requested to provide the financial means to establish a validation of the tech-nology and determine the applications potential as a new cancer treatment over a 2-3 year period. The initial funding would enable the completion of a final point of validation where the company would be in a strong position to form favorable collaborations or partnerships and be eligible for further financing where an early investor would be in an optional exit position with a potentially significant profit to the original investment.

Officers and Directors:Mark Grier, CSO and Founder

Contact Information:Mark Grier55 Station Landing #336Medford, MA 02155Phone: 857-222-8544fax: (781) [email protected]://www.synthegenixpharma.com

68 Exhibitors


University of Massachusetts Medical SchoolPresented by:Paul D. Kaufman, Professor

Product/Technology ProfileC. albicans is the most widespread fungal pathogen of humans and one of the most frequent hospital-acquired infections. The estimated an-nual cost of treating nosocomial Candida infections exceeds $1 billion per year. As an opportunistic pathogen, it is responsible for common clinical problems including oral thrush and vaginitis, but can also lead to life-threatening systemic infections (candidiasis) in immunocompro-mised individuals such as AIDS patients, resulting in 30-50% mortality rates. Contributing to these problems is the ability of C. albicans to develop resistance to antifungal drugs. Moreover, most effective anti-fungal drugs also cause serious side effects, in many cases because of the significant homology between mammalian and fungal drug targets. Therefore, new antifungal drugs are a high medical priority.

We have identified a small molecule that inhibits adhesion of C. albi-cans to polystyrene and to cultured human epithelial cells. Importantly, this compound in non-toxic to human cells. This compound also blocks hyphae formation by Candida. This transition contributes to patho-genesis, because hyphae facilitate cellular invasion and escape from phagocytes. Therefore, our compound has two activities, inhibition of adhesion and inhibition of morphogenesis, and both would be favor-able for an antifungal therapeutic.

Moreover, this compound is able to coat plastic surfaces and make them resistant to colonization by fungal biofilms. Therefore, this compound could prevent multiple types of unwanted microbial colonization, and therefore has the potential to be widely useful as a novel therapeutic and/or as a coating on medical devices. We seek to find medical device manufacturing partners to leverage our existing data and expertise in order to find the best use for our discoveries.

Market potential As mentioned above, the market for antifungal therapeutics is significant. The UMASS Office of Technol-ogy Management (OTM) assessment of the market has concluded that there would be significant interest in novel therapeutics at the big pharma level. Currently, most treatments are no longer on patent and often have issues with toxicity. Novel compounds that are targeted and effective with low toxicity would be of in-terest for development for the treatment of a growing population with a need for these types of medications. Additional potential markets exist in manufacturing, food processing, building material treatments and other materials outside of medical uses as well. .

Future Financial PlansNon-therapeutic uses: We are looking for funding to support further validation of the inhibition of fungal adhe-sion on surfaces that are non-biological in nature.

Therapeutic uses: We seek to obtain funding support to ramp up to pre-clinical studies, bringing the technol-ogy closer to a commercializable stage.

Officers and Directors:Paul D. Kaufman, Professor

Contact Information:Paul D. Kaufman,Program in Molecular MedicineUMass Medical School364 Plantation St. #506Worcester, MA 01605Phone: 508-856-5016Fax: [email protected]://www.umassmed.edu/Con-tent.aspx?id=133724#kaufman

Exhibitors 69


ZS Genetics, Inc.Presented by:Thomas Abert, Vice President

Company Overview ZS Genetics is a New England-based company with a revolutionary new approach to DNA sequencing. Having recently achieved Proof of Concept, ZSG is now preparing to commercialize its Third Generation Sequencing (3GS) system, with read lengths of 10,000 – 50,000 base pairs and single molecule capability. The patented technology uses an electron microscope (EM) and patented DNA labeling chemistry to read DNA sequences directly from microscope images.

Product/Technology ProfileZSG is now commercializing its Third Generation Sequencing (3GS) system, with read lengths of 10,000 – 50,000 base pairs and single molecule capability. The patented technology uses an electron mi-croscope (EM) and patented DNA labeling chemistry to read DNA se-quences directly from microscope images.

Market and Application The global DNA sequencing market has passed the $1 billion and grows at over 10%, even in a weak econ-omy. The global market is projected to reach $3.3 billion by 2015.

Commercial Opportunity Initial customers are the major research institution, such as the Broad Institute, Beijing Genomics in Asia, and the Sanger Institute in the UK. We are following the successful approaches of the past

Stage 1: During development collaborate with key opinion leaders from the leading genomic research • centers, co-development of key applications, data generation, publications and lead generation.Stage 2: Trial customers use the ZSG facilities to run experiments; demonstrate value of technol-• ogy.Stage 3: Sales and installation at research centers and service labs world-wide in conjunction with • ZSG vendor partners.

Competitive AdvantagesNo other sequencing approach can provide long read lengths and single molecule capabilities. ZSG projects that its technology will result in high-quality genetic sequencing with the exceptional advantage of extremely long read-lengths and single molecule sampling. The Company’s technology is expected to sequence an entire human genome in days instead of weeks, including the critical sections that current technologies can’t read at all. ZSG’s technology will solve problems that are unsolvable with competing technologies, and do so at a lower cost. The implications are enormous; for example, a pharmaceutical company could completely determine the genetic basis of a disease in months, instead of decades.

Future Financial PlansThe Company is seeking to raise funds to complete its prototype system and begin customer demonstra-tions. We are seeking $8 – 10 million for this stage.

Officers and Directors:Thomas Abert, Vice President

Contact Information:Thomas Abert8 Hidden Pond LaneNo. Reading, MA 01864Phone: 603.847.9143Fax: [email protected]

70


Notes


71

Notes

72


Notes

technology transfer center (mttc) and the massachusetts...

Documents